

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number  
**WO 01/48183 A3**

(51) International Patent Classification<sup>7</sup>: **C12N 15/10**,  
9/22, C07K 14/435, C12N 15/66, 15/70, 1/00

(74) Agent: **BAYLISS, Geoffrey**, Cyril; Boulton Wade Tennant,  
Verulam Gardens, 70 Gray's Inn Road, London WC1X  
8BT (GB).

(21) International Application Number: **PCT/EP00/13149**

(22) International Filing Date:  
22 December 2000 (22.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
9930691.2 24 December 1999 (24.12.1999) GB

(71) Applicant (for all designated States except US): **DEV-  
GEN NV** [BE/BE]; Technologiepark 9, B-9052 Zwij-  
naarde (BE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— with international search report

(88) Date of publication of the international search report:  
6 December 2001

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

(57) Abstract: There are described ways of improving the efficiency of double stranded RNA inhibition as a method of inhibiting gene expression in nematode worms such as *C. elegans*. In particular, the invention relates to the finding that changes in the genetic background of *C. elegans* result in increased sensitivity to double-stranded RNA inhibition.

BEST AVAILABLE COPY



**WO 01/48183 A3**

IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA  
INHIBITION

5       The present invention is concerned with ways of  
improving the efficiency of double stranded RNA  
inhibition as a method of inhibiting gene expression  
in nematode worms such as *C. elegans*. In particular,  
the invention relates to the finding that the  
susceptibility of nematode worms such as *C. elegans* to  
10       double stranded RNA inhibition is affected by changes  
in the genetic background of the worms.

It has recently been described in Nature Vol 391,  
pp.806-811, February 98, that introducing double  
stranded RNA into a cell results in potent and  
15       specific interference with expression of endogenous  
genes in the cell, which interference is substantially  
more effective than providing either RNA strand  
individually as proposed in antisense technology. This  
specific reduction of the activity  
20       of the gene was also found to occur in the nematode  
worm *Caenorhabditis elegans* (*C. elegans*) when the RNA  
was introduced into the genome or body cavity of the  
worm.

The present inventors have utilized the double  
25       stranded RNA inhibition technique and applied it  
further to devise novel and inventive methods of (i)  
assigning functions to genes or DNA fragments which  
have been sequenced in various projects, such as, for  
example, the human genome project and which have yet  
30       to be accorded a particular function, and (ii)  
identifying DNA responsible for conferring a  
particular phenotype. Such methods are described in  
the applicant's co-pending application number WO  
00/01846. Processes for introducing RNA into a living  
35       cell, either *in vivo* or *ex vivo*, in order to inhibit  
expression of a target gene in that cell are

CONFIRMATION COPY

additionally described in WO 99/32619.

Several different experimental approaches can be used to introduce double-stranded RNA into nematode worms in order to achieve RNA interference *in vivo*.

5 One of the most straightforward approaches is simple injection of double-stranded RNA into a body cavity. A more elegant solution is to feed the nematodes on food organisms, generally bacteria, which express a double stranded RNA of the appropriate sequence,  
10 corresponding to a region of the target gene.

The present inventors have now determined that the phenomenon of RNA interference in nematodes following ingestion of food organisms capable of expressing double-stranded RNA is dependent both on  
15 the nature of the food organism and on the genetic background of the nematodes themselves. These findings may be exploited to provided improved methods of double-stranded RNA inhibition.

Therefore, according to a first aspect of the  
20 present invention there is provided a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence  
25 substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild  
30 type.

*Caenorhabditis elegans* is the preferred nematode worm for use in the method of the invention although the method could be carried out with other nematodes and in particular with other microscopic nematodes,  
35 preferably microscopic nematodes belonging to the genus *Caenorhabditis*. As used herein the term "microscopic" nematode encompasses nematodes of

approximately the same size as *C. elegans*, being of the order 1mm long in the adult stage. Microscopic nematodes of this approximate size can easily be grown in the wells of a multi-well plate of the type  
5 generally used in the art to perform mid- to high-throughput screening.

It is an essential feature of this aspect of the invention that the nematode has a non wild-type genetic background which confers greater sensitivity  
10 to RNA interference phenomena (abbreviated herein to RNAi) as compared to the equivalent wild type nematodes. As illustrated in the accompanying examples, introduction of double-stranded RNA (abbreviated herein to dsRNA) into a non wild-type  
15 strain according to the invention results in greater inhibition of expression of the target gene. Depending on the nature of the target gene, this greater level of inhibition may be detectable at the phenotypic level as a more pronounced phenotype.

The nematode having non wild-type genetic background may, advantageously, be a mutant strain. Mutations which have the effect of increasing susceptibility of the nematode to RNAi may, for  
20 example, affect the stability of dsRNA or the kinetics of dsRNA turnover within cells of the worm or the rate of uptake of dsRNA synthesised by a food organism. Suitable mutant strains include mutant strains exhibiting knock-out or loss-of-function mutations in  
25 one or more genes encoding proteins involved in RNA synthesis, RNA degradation or the regulation of these processes.  
30

In one preferred embodiment, the nematode is a mutant strain, more preferably a mutant *C. elegans*, which exhibits reduced activity of one or more  
35 nucleases compared to wild-type. Suitable strains include mutant strains exhibiting knock-out or loss-of-function mutations in one or more genes encoding

nucleases, such as RNases. A particularly preferred example is the *nuc-1* strain. This mutant *C. elegans* strain is known per se in the art.

5 In a second preferred embodiment, the nematode is a mutant strain, more preferably a mutant *C. elegans*, which exhibits increased gut uptake compared to wild-type. Particularly preferred examples of such strains are the so-called *C. elegans* gun mutants described herein. In a still further embodiment, the nematode  
10 may be a transgenic worm comprising one or more transgenes which increase gut uptake relative to wild-type.

The term "increased gut uptake" as used herein is taken to mean increased uptake of foreign particles  
15 from the gut lumen and may encompass both increased gut permeability and increased gut molecular transport compared to wild-type *C. elegans*.

*C. elegans* feeds by taking in liquid containing its food (e.g. bacteria). It then spits out the  
20 liquid, crushes the food particles and internalises them into the gut lumen. This process is performed by the muscles of the pharynx. The process of taking up liquid and subsequently spitting it out is called pharyngeal pumping. Once the food particles have been  
25 internalised via pharyngeal pumping their contents must cross the gut itself in order to reach target sites in the worm. There are multiple factors which effect the uptake of compounds from the gut lumen to the surrounding tissues. These include the action of  
30 multi-drug resistance proteins, multi-drug resistance related proteins and the P450 cytochromes as well as other enzymes and mechanisms available for transport of molecules through the gut wall.

*C. elegans* mutants which exhibit increased uptake  
35 of foreign molecules through the gut may be obtained from the *C. elegans* mutant collection at the C.

*C. elegans* Genetic Center, University of Minnesota, St Paul, Minnesota, or may be generated by standard methods. Such methods are described by Anderson in Methods in Cell Biology, Vol 48, "C. *elegans*: Modern biological analysis of an organism" Pages 31 to 58. Several selection rounds of the PCR technique can be performed to select a mutant worm with a deletion in a desired gene. Alternatively, a population of worms could be subjected to random mutagenesis and worms exhibiting the desired characteristic of increased gut uptake selected using a phenotypic screen, such as the dye uptake method described herein.

As an alternative to mutation, transgenic worms may be generated with the appropriate characteristics. Methods of preparing transgenic worms are well known in the art and are particularly described by Craig Mello and Andrew Fire, Methods in Cell Biology, Vol 48, Ed. H.F. Epstein and D.C. Shakes, Academic Press, pages 452-480.

Worms exhibiting the desired characteristics of increased gut uptake can be identified using a test devised by the inventors based on uptake of a marker precursor molecule which is cleaved by the action of enzymes present in the gut lumen to generate a marker molecule which produces a detectable signal, such as fluorescence. A suitable marker precursor molecule is the fluorescent dye precursor BCECF-AM available from Molecular Probes (Europe BV), Netherlands. This dye only becomes fluorescent when cleaved by esterases and maintained at a pH above 6. The pH of the gut lumen is usually 5 or below. Thus, any BCECF-AM taken up through the pharynx into the gut lumen is not fluorescent until cleaved and the cleaved portion has entered the cells surrounding the lumen which are at a higher pH. Thus, this dye is able to quickly identify mutant or otherwise modified worms which have increased gut transport or permeability. There is a

gradual increase in fluorescence in the tissues surrounding the gut while the gut lumen remains dark. The fluorescence can be detected at an excitation wavelength of 485 nm and an emission wavelength of 530 nm.

Specific examples of gun mutant strains isolated using this procedure which may be used in the method of the invention are strains bg77, bg84, bg85 and bg86, although it is to be understood that the invention is in no way limited to the use of these specific strains. The *C. elegans* gun mutant strain bg85 was deposited on 23 December 1999 at the BCCM/LMG culture collection, Laboratorium Voor Microbiologie, Universiteit Gent, K. L. Ledeganckstraat 35, B-9000, Gent, Belgium under accession number LMBP 5334CB. The phrase "the bg85 mutation" as used herein refers to the specific mutation(s) present in the bg85 strain which is/are responsible for conferring the gun phenotype.

It is also within the scope of the invention to use a non wild-type nematode strain, preferable a *C. elegans* strain, having multiple mutations which affect sensitivity to RNAi. A preferred type of multiple mutant is one having at least one mutation which results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type. An example of such a mutant is a *C. elegans* strain having the *nuc-1* mutation and at least one further gun mutation. As exemplified herein, double mutants having the *nuc-1* mutation and a gun mutation exhibit enhanced sensitivity to RNAi as compared to either *nuc-1* or gun single mutants.

For the avoidance of doubt, where particular characteristics or properties of nematode worms are described herein by relative terms such as "enhanced"

or "increased" or "decreased" this should be taken to mean enhanced, increased or decreased relative to wild-type nematodes. In the case of *C. elegans*, wild-type is defined as the N2 Bristol strain which is well known to workers in the *C. elegans* field and has been extremely well characterised (see Methods in Cell Biology, Volume 48, *Caenorhabditis elegans*: Modern biological analysis of an organism, ed. by Henry F. Epstein and Diane C. Shakes, 1995 Academic Press; The nematode *Caenorhabditis elegans*, ed. by William Wood and the community of *C. elegans* researchers., 1988, Cold Spring Harbor Laboratory Press; *C. elegans* II, ed. by Donald L. Riddle, Thomas Blumenthal, Barbara J. Meyer and James R. Priess, 1997, Cold Spring Harbor Laboratory Press). The N2 strain can be obtained from the *C. elegans* Genetic Center, University of Minnesota, St Paul, Minnesota, USA.

The food organism for use in the above aspect of the invention is preferably a bacterium such as, for example, a strain of *E.coli*. It will, however, be appreciated that any other type of food organism on which nematodes feed and which is capable of producing dsRNA could be used. The food organism may be genetically modified to express a double-stranded RNA of the appropriate sequence, as will be understood with reference to the examples included herein. One convenient way in which this may be achieved in a bacterial food organism is by transforming the bacterium with a vector comprising a promoter or promoters positioned to drive transcription of a DNA sequence to RNA capable of forming a double-stranded structure. Examples of such vectors will be further described below.

The actual step of feeding the food organism to the nematode may be carried out according to procedures known in the art, see WO 00/01846.



Typically the feeding of the food organisms to the nematodes is performed on standard agar plates commonly used for culturing *C. elegans* in the laboratory. However, the step of feeding the food  
5 organism to the nematodes may also be carried out in liquid culture, for example in the wells of 96-well microtitre assay plates.

The inventors have further observed that variations in the food organism can result in enhanced  
10 *in vivo* RNAi when the food organism is ingested by a nematode worm.

Accordingly, in a further aspect the invention provides a method of inhibiting expression of a target gene in a nematode worm comprising feeding to said  
15 nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a  
20 modification selected to provide increased expression or persistence of the double-stranded RNA compared to a food organism which does not carry the modification.

The modification present in the food organism can be any modification which results in increased  
25 expression of the dsRNA or in increased persistence of the dsRNA. Suitable modifications might include mutations within the bacterial chromosome which affect RNA stability and/or degradation or mutations which have a direct effect on the rate of transcription. In  
30 a preferred embodiment, the food organism is an RNase III minus *E. coli* strain, or any other RNase negative strain.

According to a still further aspect of the invention there is provided a method of inhibiting  
35 expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide

sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

5 In addition to exhibiting increased sensitivity to RNAi following feeding with food organisms capable of expressing a dsRNA, nematodes which exhibit increase gut uptake as described herein also show increased uptake of DNA molecules capable of producing  
10 double-stranded RNA structures following ingestion into a nematode.

In a preferred embodiment, the DNA is in the form of a vector comprising a promoter or promoters orientated to relative to a sequence of DNA such that  
15 they are capable of driving transcription of the said DNA to make RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to the promoter or promoters.

Several different arrangements of promoters may  
20 be used in such a vector. In a first arrangement a DNA fragment corresponding to a region of the target gene is flanked by two opposable polymerase-specific promoters which are preferably identical. Transcription from the opposable promoters produces  
25 two complementary RNA strands which can anneal to form an RNA duplex. The plasmid pGN1 described herein is an example of a vector comprising two opposable T7 promoters flanking a multiple cloning site for insertion of a DNA fragment of the appropriate  
30 sequence, corresponding to a region of a target gene. pGN8 is an example of a vector derived from pGN1 containing a fragment of the *C. elegans unc-22* gene. In an alternative arrangement, DNA fragments corresponding to a region of the target gene may be  
35 placed both in the sense and the antisense orientation downstream of a single promoter. In this case, the sense/antisense fragments are co-transcribed to

generate a single RNA strand which is self-complementary and can therefore form an RNA duplex.

In both of the above arrangements, the polymerase-specific T3, T7 and SP6 promoters, all of which are well known in the art, are useful for driving transcription of the RNA. Expression from these promoters is dependent on expression of the cognate polymerase. Advantageously, the nematode itself may be adapted to express the appropriate polymerase. Expression of the polymerase may be general and constitutive, but could also be regulated under a tissue-specific promoter, an inducible promoter, a temporally regulated promoter or a promoter having a combination of such characteristics. Transgenic *C. elegans* strains harboring a transgene encoding the desired polymerase under the control of an appropriately-regulated promoter can be constructed according to methods known *per se* in the art and described, for example, by Craig Mello and Andrew Fire in *Methods in Cell Biology*, Vol 48, Ed. H. F. Epstein and D. C. Shakes, Academic Press, pp 452-480.

The advantage of adapting the nematode to express the required polymerase is that it is possible to control inhibition of expression of the target gene in a tissue-specific and/or temporally specific manner by placing expression of the polymerase under the control of an appropriately regulated promoter.

Introduction of DNA into nematodes in accordance with the method of the invention can be achieved using a variety of techniques, for example by direct injection into a body cavity or by soaking the worms in a solution containing the DNA. If the DNA is in the form of a vector as described herein, e.g. a plasmid harboring a cloned DNA fragment between two flanking T7 promoters, then dsRNA corresponding to this DNA fragment will be formed in the nematode resulting in down regulation of the corresponding gene. The

introduced DNA can form an extrachromosomal array, which array might result in a more catalytic knock-out or reduction of function phenotype. The DNA might also become integrated into the genome of the nematode, resulting in the same catalytic knock out or reduction of function phenotype, but which is stably transmittable.

In each aspect of the invention, the double-stranded RNA structure may be formed by two separate complementary RNA strands or a single self-complementary strand, as described above. Inhibition of target gene expression is sequence-specific in that only nucleotide sequences corresponding to the duplex region of the dsRNA structure are targeted for inhibition.

It is preferred to use dsRNA comprising a nucleotide sequence identical to a portion of the target gene, although RNA sequences with minor variations such as insertions, deletions and single base substitutions may also be used and are effective for inhibition. It will be readily apparent that 100% sequence identity between the dsRNA and a portion of the target gene is not absolutely required for inhibition and the phrase "substantially identical" as used herein is to be interpreted accordingly. Generally sequences which are substantially identical will share at least 90%, preferably at least 95% and more preferably at least 98% nucleic acid sequence identity. Sequence identity may be conveniently calculated based on an optimal alignment, for example using the BLAST program accessible at [WWW.ncbi.nlm.nih.gov](http://WWW.ncbi.nlm.nih.gov).

The invention will be further understood with reference to the following non-limiting Examples, together with the accompanying Figures in which:

Figure 1 is a plasmid map of the vector pGN1

containing opposable T7 promoters flanking a multiple cloning site and an ampicillin resistance marker.

5 Figure 2 is a plasmid map of the vector pGN8 (a genomic fragment of the *C. elegans* *unc-22* gene cloned in pGN1).

10 Figure 3 is a plasmid map of the vector pGN29 containing two T7 promoters and two T7 terminators flanking *Bst*XI sites. This vector permits cloning of DNA fragments linked to *Bst*XI adaptors.

15 Figure 4 is a plasmid map of the vector pGN39 containing two T7 promoters and two T7 terminators flanking attR recombination sites (based on the Gateway™ cloning system of Life Technologies, Inc).

20 Figure 5 is a plasmid map of the vector pGX22 (a fragment of the *C. elegans* gene C04H5.6 cloned in pGN29).

25 Figure 6 is a plasmid map of the vector pGX52 (a fragment of the *C. elegans* gene K11D9.2b cloned in pGN29).

Figure 7 is a plasmid map of the vector pGX104 (a fragment of the *C. elegans* gene Y57G11C.15 cloned in pGN29).

30 Figure 8 is a plasmid map of the vector pGZ8 (a fragment of the *C. elegans* gene T25G3.2 cloned in pGN39).

35 Figure 9 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the

plasmid pGX22.

Figure 10 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the plasmid pGX52.

Figure 11 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the plasmid pGXGZ8.

Figure 12 shows the results of an RNAi experiment in which wild-type (N2) or *nuc-1* strain *C. elegans* in liquid culture were fed with *E. coli* containing the plasmid pGX104

**Example 1**

Influence of genetic background on the efficiency of RNAi in *C. elegans*.

**5 Introduction**

Various different *C. elegans* strains were fed with different bacteria, to test the possibility of RNAi by feeding *C. elegans* with bacteria that produce dsRNA. The possibility of DNA delivery and dsRNA delivery has previously been envisaged by using different bacterial strains. In this experiment the importance of the *C. elegans* strain as receptor of the dsRNA is also shown.

For this experiment the following *E. coli* strains were used:

1. MC1061: F-*araD139*  $\Delta$ (*ara-leu*)7696 *galE15 galK16*  $\Delta$ (*lac*)X74 *rpsL* (*Str<sup>r</sup>*) *hsdR2* (*r<sub>k</sub><sup>-</sup> m<sub>k</sub><sup>+</sup>*) *mcrA mcrB1*  
- regular host for various plasmids,  
- Wertman et al., (1986) Gene 49:253-262,  
- Raleigh et al., (1989) in Current Protocols in Molecular Biology eds. Ausubel et al, Publishing associates and Wiley Interscience; New York. Unit 1.4.
2. B21(DE3): F- *ompT(lon)* *hsdS<sub>B</sub>* (*r<sub>B</sub><sup>-</sup> m<sub>B</sub><sup>-</sup>*; an *E. coli* B strain) with DE3, a  $\lambda$  prophage carrying the T7 RNA polymerase gene.  
- regular host for IPTG inducible T7 polymerase expression,  
- Studier et al. (1990) Meth. Enzymol. 185:60-89
3. HT115 (DE3): F- *mcrA mcrB* IN(*rrnD-rrnE*) 1  $\lambda$ -*rnc14::tr10* (DE3 lysogen: *lacUV5* promoter-T7polymerase)  
- host for IPTG inducible T7 polymerase

expression,

- RNaseIII-,

- Fire A, Carnegie Institution, Baltimore, MD,  
Pers. Comm.

5

For this experiment the following *C. elegans* strains  
were used:

1. *C. elegans* N2: regular WT laboratory strain
2. *C. elegans* nuc-1(e1393): *C. elegans* strain with a  
reduced endonuclease activity (>95%); condensed  
chromatin persists after programmed cell death;  
ingested (bacterial) DNA in the intestinal lumen  
is not degraded. Several alleles are described:  
e1392 (strong allele: has been used for the  
experiments described below); n887 (resembles  
e1392) and n334 (weaker allele)  
- Stanfield et al. (1998) East Coast Worm  
meeting abstract 171,  
- Anonymous, Worm Breeder's Gazette 1(1):17b  
Hevelone et al. (1988) Biochem. Genet. 26:447-461  
- Ellis et al., Worm breeder's Gazette 7(2):44  
- Babu, Worm Breeder's gazette 1(2):10  
- Driscoll, (1996) Brain Pathol. 6:411-425  
- Ellis et al., (1991) Genetics 129:79-94

For this experiment the following plasmids were used:

- pGN1: A vector encoding for ampicillin resistance,  
harbouring a multiple cloning site between two  
convergent T7 promoters.
- pGN8: pGN1 containing a genomic fragment of *unc-22*.  
Decreased *unc-22* expression via RNAi results in a  
"twitching" phenotype in *C. elegans*.



**Experimental conditions**

12-well micro-titer plates were filled with approximately 2 ml of NGM agar per well (1 litre of NGM agar: 15g Agar, 1g peptone, 3g NaCl, 1ml cholesterol solution (5 mg/ml in EtOH), with sterile addition after autoclaving of 9.5 ml 0.1M CaCl<sub>2</sub>, 9.5 ml 0.1 ml MgSO<sub>4</sub>, 25 ml 1M KH<sub>2</sub>PO<sub>4</sub>/K<sub>2</sub>HPO<sub>4</sub> buffer pH 6 and 5 ml nystatin solution (dissolved 10 mg/ml in 1:1 EtOH:CH<sub>3</sub>COONH<sub>4</sub> 7.5 M).

10 The dried plates were spotted with approximately 50 µl of an overnight culture of bacteria. When IPTG induction was required, 50 µl of a 10 mM stock solution of IPTG was dropped on top of the bacteria lawn, and incubated at 37°C for approximately 4 hours. Individual nematodes at the L4 growth stage were then placed in single wells. In each well 4 nematodes, and the plates were further incubated at 20°C for 6 days to allow offspring to be formed. The F1 offspring of the seeded nematodes were tested for the twitching phenotype.

**Results**

Table 1: Percentage of the offspring that show the twitching phenotype

5	<b>MC1061</b>	<b>N2</b>	<b><i>nuc-1</i></b>
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	0%	0%
	pGN8 + IPTG	0%	0%
10	<b>BL21 (DE3)</b>		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	20% (+)	>90% (++)
	pGN8 + IPTG	20% (+)	>90% (++±)
15	<b>HT115 (DE3)</b>		
	pGN1	0%	0%
	pGN1 + IPTG	0%	0%
	pGN8	50% (±)	>90% (++)
20	pGN8 + IPTG	80% (++)	>90% (+++)

20 %: percentage twitchers

+: weak twitching

++: twitching

+++: strong twitching

25

**Conclusions**

The experiment with *E. coli* MC1061 shows that no twitching could be observed in this experiment.

30

Neither the N2 nematodes nor the *nuc-1* nematodes showed any twitchers. This is to be expected as *E. coli* MC1061 does not produce any T7 RNA polymerase, and hence the *unc-22* fragment cloned in pGN8 is not

expressed as dsRNA.

5 The experiment with *E. coli* strain BL21(DE3) and  
nematode strain N2 shows expected results. BL21(DE3)  
harbouring plasmid pGN1 does not result in any  
twitching as the pGN1 vector is an empty vector. BL21  
(DE3) harbouring PGN8 results in the expression of  
unc-22 dsRNA. When this dsRNA is fed to the N2  
10 nematode (indirectly by feeding with the bacteria that  
produce the dsRNA), this results in a twitching  
phenotype, indicating that the dsRNA is able to pass  
the gut barrier and is able to perform its interfering  
activity.

15 Surprisingly the RNAi effect of the unc-22 dsRNA was  
even more pronounced in *C. elegans* strain *nuc-1* than  
in the wild type N2 strain. Although one may expect  
that the *nuc-1* mutation results in the non-degradation  
or at least in a slower degradation of DNA, as the  
20 NUC-1 protein is known to be involved in DNase  
activity, we clearly observe an enhancement of the  
RNAi induced phenotype in *C. elegans* with a *nuc-1*  
background. The *nuc-1* mutation has not been cloned  
yet, but it has been described that the gene is  
25 involved in nuclease activity, and more particularly  
DNase activity. If the NUC-1 protein is a nuclease, it  
may also have activity on nuclease activity on dsRNA,  
which would explain the enhanced RNAi phenotype. The  
*nuc-1* gene product may be a nuclease, or a regulator  
30 of nuclease activity. As the mode of action of RNAi is  
still not understood, it is also possible that the  
NUC-1 protein is interfering in the mode of action of  
RNAi. This would explain why a *nuc-1* mutant is more  
sensitive to RNAi.

35

The experiment with the *E. coli* strain HT115 (DE3)

confirms the experiments with the BL21(DE3) strain. The RNA interference observed with the unc-22 dsRNA is even higher. In comparison with strain BL21(DE3) this could be expected, as HT115(DE3) is a RNase III minus strain, and hence is expected to produce larger amounts of dsRNA, resulting in more prominent RNAi. This indicates further that the RNAi observed in this experiment is the result of the dsRNA produced by the bacteria fed to the *C. elegans*. Feeding *C. elegans* nuc-1 with HT115(DE3) harbouring pGN8 also results in higher RNA interference phenotype than feeding the same bacteria to *C. elegans* wild-type strain N2. Once again this indicates that improved RNAi can be realised using a nuclease negative *C. elegans* and more particularly with a with the *C. elegans* nuc-1 (e1392) strain.

#### Summary

RNA interference can be achieved in *C. elegans* by feeding the worms with bacteria that produce dsRNA. The efficiency of this RNA interference is dependent both on the *E. coli* strain and on the genetic background of the *C. elegans* strain. The higher the level of dsRNA production in the *E. coli*, the more RNAi is observed. This can be realised by using efficient RNA expression systems such as T7 RNA polymerase and RNAase negative strains, such as RNaseIII minus strains. In this example the level of dsRNA production varied: HT115(DE3) > BL21(DE3) > MC1061.

RNA interference is high in *C. elegans* strains that are nuclease negative, or that are influenced in their nuclease activity. This can be realised by using a mutant strain such as *C. elegans* nuc-1. In this example the sensitivity to RNAi varied: *C. elegans* nuc-1 >> *C. elegans* N2

**Example 2**

Improved RNAi by feeding dsRNA producing bacteria in selected *C. elegans* strains-Comparison of the *nuc-1* strain with several mutants which show improved gut uptake. (designated herein 'gun' mutants). Strains bg77, bg78, bg83, bg84, bg85, bg86, bg87, bg88 and bg89 are typical gun mutant *C. elegans* strains isolated using selection for increased gut uptake (gun phenotype) with the marker dye BCECF-AM.

**Experimental conditions:**

- 12-well micro-titer plates were filled with approximately 2ml of NGM agar (containing 1ml/l of ampicillin (100µg/ml) and 5 ml of 100mM stock IPTG) per well
- the dried plates were spotted with 25µl of an overnight culture of bacteria (BL21DE3/HT115DE3) containing the plasmids pGN1 (T7prom-T7prom) or pGN8 (T7prom-unc-22-T7prom)
- individual nematodes at the L4 growth stage were then placed in single wells, one nematode per well
- the plates were incubated at 20°C for 6 days to allow offspring to be formed
- the adult F1 offspring of the seeded nematodes were tested for the twitching phenotype

**Results:**

Table 2:

	20°C/6d	pGN1 HT115DE3	pGN8 BL2DE3	pGN8 HT115DE3	
5	N2	0	1	1	
	bg77	0	1-2	3	
	bg78	0	1	1-2	
	bg83	0	1	1	
10	bg84	0	1-2	3	
	bg85	0	1	2-3	
	bg86	0	1	2-3	
	bg87	0	1	1	
	bg88	0	1	1	
15	bg89	0	1	1	

## figure legend:

- 0 = no twitching  
 1 = no to weak phenotype  
 2 = clear phenotype  
 3 = strong phenotype

25 **Conclusions**

- bacterial strain HT115(DE3) shows a better RNAi sensitivity than bacterial strain BL21(DE3)
- the *nuc-1* *C. elegans* strain is a better strain than the Wild-type N2 strain for RNAi sensitivity
- various gun mutants (improved gut uptake mutants) and more particularly the gun mutant strains bg77, bg84, bg85, bg86 show improved sensitivity to RNAi compared to Wild-type.

A double mutant *C. elegans* strain (nuc-1/gun) shows even greater sensitivity to RNAi compared to wild-type:

5 Double mutants were constructed to test the prediction that gun/nuc mutants would even show more enhanced RNAi sensitivity. As an example, the crossing strategy with gun strain bg85 is shown, similar crosses can be conducted with other gun strains, such as bg77, bg84 and bg86.

P0 cross: gun(bg85) x WT males

15 F1 cross: nuc-1 x gun(bg85)/+ males

F2 cross: nuc-1 x gun(bg85)/+; nuc-1/0 males (50%)  
nuc-1 x +/+; nuc-1/0 males (50%)

20 F3 single: gun(bg85)/+; nuc-1 hermaphrodites (25%)  
+/+; nuc-1 hermaphrodites (75%)

F4 single: gun(bg85); nuc-1 (1/4 of every 4th plate high staining with BCECF)

25 F5 retest: gun(bg85); nuc-1 (100% progeny of F4 singled high staining with BCECF)

To select for the gun phenotype, the fluorescence precursor BCECF-AM is used (obtainable from Molecular probes). The precursor BCECF-AM is cleaved by esterases present in the gut of the worm to generate the dye BCECF which is fluorescent at pH values above 6. This allows selection for worms that have a gun phenotype. BCECF-AM is taken up through the pharynx into the gut lumen and is not fluorescent until it has been cleaved, and the BCECF portion has entered the

cells surrounding the lumen. Wild-type worms will show slower or no increase in BCECF fluorescence.

5     **Example 3**

Improved RNAi feeding in liquid culture using *nuc-1(e1393)* *C. elegans*.

**Introduction**

10    N2 and *nuc-1* *C. elegans* strains were fed with bacteria producing dsRNAs that give lethal phenotypes via RNAi. For this example RNAi was performed in liquid culture instead of on agar plates. We show here for a number of genes that the RNAi effect is more penetrant using  
15    the *nuc-1* strain than the N2 strain, and that RNAi can be performed in liquid.

For this experiment the following *E. coli* strains were used:

20

1.    HT115 (DE3): F- *mcrA mcrB* IN(*rrnD-rrnE*) 1  $\lambda$ -*rncl4::trl0* (DE3 lysogen: lacUV5 promoter -T7 polymerase)
  - host for IPTG inducible T7 polymerase expression
  - 25    - RNaseIII<sup>-</sup>
  - Fire A, Carnegie Institution, Baltimore, MD, Pers. Comm.

25

For this experiment, following *C. elegans* strains were used:

30

1. *C. elegans* N2: regular WT laboratory strain
2. *C. elegans nuc-1(e1393)*: *C. elegans* strain with a  
35    reduced endonuclease activity (>95%); condensed chromatin persists after programmed cell death;

35



- ingested (bacterial) DNA in the intestinal lumen is not degraded. Several alleles are described: e1392 (strong allele: has been used for the experiments described below); n887 (resembles e1392) and n334 (weaker allele)
- 5                   - Stanfield et al. (1998) East Coast Worm meeting abstract 171
- Anonymous, Worm Breeder's Gazette 1(1):17b
- Hevelone et al. (1988) Biochem. Genet. 26:447-461
- 10                  - Ellis et al., Worm breeder's Gazette 7(2):44
- Babu, Worm Breeder's gazette 1(2):10
- Driscoll, (1996) Brain Pathol. 6:411-425
- Ellis et al., (1991) Genetics 129:79-94

15

For this experiment, the following plasmids that all give lethal phenotypes in *C. elegans* via RNAi were used:

- 20       pGX22: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid C04H5.6 corresponding to a member of the RNA helicase family.

- 25       pGX52: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid K11D9.2b corresponding to sarco/endoplasmic Ca<sup>2+</sup> ATPase also known as SERCA.

- 30       pGZ18: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid T25G3.2 corresponding to a chitin like synthase gene.

- 35       pGX104: a vector encoding ampicillin resistance, containing a genomic fragment of cosmid Y57G11C.15 corresponding to sec-61, a transport protein.

**Experimental conditions**

- 5       - 1 ml overnight cultures of HT115 (DE3) bacteria containing the plasmids pGX22, pGX52, pGZ18 or pGX104 respectively were pelleted and resuspended in S-complete medium, containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.
- 10       - 10 µl of this bacterial solution was transferred to a 96-well microtiter plate already filled with 100 µl S-complete containing 1ml/l of ampicillin (100 µg/ml) and 1ml/l of 1000mM IPTG.
- 15       - 3 nematodes at the L1 growth stage of N2 and nuc-1 strain were then placed in single wells, 3 L1's per well. Per experimental set up, 16 wells were used (n=16).
- 20       - the plates were incubated at 25°C for 5 days to allow offspring to be formed.
- 25       - the plates were visually checked and the following phenotypes could be scored per individual well:
  - 25       **no effect:** L1's developed to adults and gave normal offspring.
  - 30       **no F1 offspring:** L1's developed to adults and gave no offspring.
  - 30       **acute lethal:** original L1 did not mature and died.

**Results**

- 35       The results of this experiment are illustrated graphically in Figures 9 to 12. Data are expressed as

a percentage of the total (n=16) on the y-axis for both N2 and *nuc-1* strains.

### Conclusions

5 The following genes were tested in this liquid RNAi assay:

- C04H5.6: an RNA helicase. RNAi of this gene interferes with the generation of offspring.
- 10 - SERCA: a sarco/endoplasmic  $\text{Ca}^{2+}$  ATPase. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- T25G3.2: a chitin like synthase gene. RNAi of  
15 this gene causes dead eggs.
- *sec-61*: a transport protein. A strong RNAi phenotype causes an acute lethal phenotype. A less penetrant RNAi effect results in loss of offspring.
- 20 - RNAi can be performed under liquid conditions.

As in the previous examples this set of experiments shows that the *nuc-1* *C. elegans* strain is more sensitive to RNAi than the wild-type N2 strain. This  
25 is most clear for less penetrant phenotypes such as SERCA and chitin synthase. For strong RNAi phenotypes like the helicase and *Sec-61* the difference between the N2 wild-type strain and the *nuc-1* strain is less pronounced.

30

**Example 4****Cloning of pGX22, pGX52, pGZ18 and pGX104 for RNAi**

A set of primers for each gene was designed on the basis of sequence data available in the publicly accessible *C. elegans* sequence database (Acedb).

The cosmid names relate to:

1. **C04H5.6**=member of RNA helicase
2. **K11D9.2b**=SERCA
3. **Y57G11C.15**=transport protein sec-61
4. **T25G3.2**=chitin synthase like

The following primer sequences were designed:

1. **C04H5.6F** 5'-TGCTCAGAGAGTTTCTCAACGAACC-3'  
**C04H5.6R** 5'-CAATGTTAGTTGCTAGGACCACTG-3'
2. **K11D9.2bF** 5'-CAGCCGATCTCCGTCTTGTG-3'  
**K11D9.2bR** 5'-CCGAGGGCAAGACAACGAAG-3'
3. **Y57G11C.15F** 5'-ACCGTGGTACTCTTATGGAGCTCG-3'  
**Y57G11C.15R** 5'-TGCAGTGGATTGGGTCTTCG-3'
4. **T25G3.2F**  
5'-GGGGACAAGTTTGTACAAAAAGCAGGCTATGCCAAGTACATGTCGATTGCG-3'  
**T25G3.2R**  
5'-GGGGACCACTTTGTACAAGAAAGCTGGGTGGAGAAGCATTCGAGAGTTTG-3'

PCR was performed on genomic DNA of N2 strain *C. elegans* to give PCR products of the following sizes:

- 1326bp for C04H5.6  
1213bp for K11D9.2b

1024bp for Y57G11C.15

1115bp for T25G3.2

- 5 The PCR fragments of C04H5.6, K11D9.2b and Y57G11C.15 were linked to *Bst*XI adaptors (Invitrogen) and then cloned into the pGN29 vector cut with *Bst*XI. pGN29 contains two T7 promoters and two T7 terminators flanking a cloning site which is adapted for facilitated cloning of PCR fragments, comprising a
- 10 stuffer DNA flanked by two *Bst*XI sites (see schematic Figure 3). The resulting plasmids were designated pGX22 (C04H5.6), pGX52 (K11D9.2b) and pGX104 (Y57G11C.15).
- 15 The PCR fragment of T25G3.2 was cloned into pGN39 via recombination sites based on the GATEWAY™ cloning system (Life Technologies, Inc). pGN39 contains two T7 promoters and two T7 terminators flanking a cloning site which facilitates "High Throughput" cloning based
- 20 on homologous recombination rather than restriction enzyme digestion and ligation. As shown schematically in Figure 4, the cloning site comprises attR1 and attR2 recombination sites from bacteriophage lambda flanking a gene which is lethal to *E. coli*, in this
- 25 case the *ccdB* gene. This cloning site is derived from the Gateway™ cloning system commercially available from Life Technologies, Inc. The Gateway™ cloning system has been extensively described by Hartley et al. in WO 96/40724 (PCT/US96/10082).

**Example 5**

Selecting *C. elegans* mutations for increased gut uptake (gun) using marker dye BCECF-AM and *unc-31* as background.

5

The screen was performed in *unc-31(e928)* mutant background, to ensure high amounts of dye in the gut lumen, since *unc-31* mutations show constitutive pharyngeal pumping. The dye (BCECF-AM: 2',7' bis (2-carboxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethylester), obtained from Molecular Probes, is cleaved by intracellular esterases. Fluorescence accumulates in the gut cells upon passage through the apical gut membrane.

15

**Mutagenesis**

Day 1: *unc-31* L4 staged worms were mutagenised with EMS (final concentration 50 mM) for 4 hours

Day 2: P0 was divided over several large agar plates

Day 6: F1's were collected and dropped on large plates. The number of eggs the F1's layed were checked every hour and de F1's were removed when 10-20 eggs per F1 were counted

Day 10: F2 adults were collected and screened with BCECF-AM. Mutations with increased staining of the gut cells after 15-30 minutes exposure to the dye were selected and singled on small agar plates.

30

About 50 initial positives gave progeny which was retested with BCECF-AM (2x) and leucine CMB (1x) 9 of the 50 strains were kept (2 strains : 3 times positive, 7 other strains : twice positive)

35

Table 3: Isolation of mutations for increased staining with BCECF-AM

Total P0	Total F1	Total F2	screened chromosomes	number of strains isolated
(counted)	(estimated)	(calculated)	(estimated)	(counted)
2251	55618	222472	100000	9

Outcrossing, backcrossing and double construction

- 10 1. backcrossing *unc-31; gun* --> *unc-31; gun*
  - *unc-31; gun* x WT males
  - singled 2x5 WT hermaphrodites F1s (*unc-31/+; gun/+*)
  - singled 50 WT hermaphrodites F2s (1/4 homozygous)
  - select strains segregating 1/4 *unc*
- 15 - stain *unc* strains with BCECF-AM
  - from positive strains pick *unc* homozygous
  - retest 100 % *unc* strains with BCECF-AM
  - kept 1 strain (backcrossed)
- 20 2. *unc-31* background was crossed out-->+; *gun*
  - *unc-31; gun* x WT males
  - singled 2x5 WT hermaphrodites F1s (*unc-31/+; gun/+*)
  - singled 50 WT hermaphrodites F2s (1/4 homozygous)
  - select strains which did not segregate *unc* F3s
- 25 anymore
  - stain non *unc* strains with BCECF-AM
  - 7 positive strains were retested with BCECF-AM and finally 1 was selected and kept (outcrossed)
- 30 3. +; *gun* (1x outcrossed) were 2 times backcrossed-->+; *gun* (3x backcrossed)
  - *gun* x WT males
  - WT hermaphrodites x F1 males (*gun/+*)
  - singled 10 WT hermaphrodites F2s (1/2 heterozygous)
- 35 - singled 50 WT hermaphrodites F3s (1/8 homozygous)

- 31 -

- stain strains with BCECF-AM- retested positives with BCECF-AM and finally 1 was selected and kept

4. *gun* (3x backcrossed) were crossed with *nuc-1(X)*  
 5 mutant--> *gun; nuc-1*  
 - *gun* x WT males  
 - *nuc-1* x *gun/+* males  
 - *nuc-1* x *gun/+; nuc-1/0* or *+/+; nuc-1/0* males  
 - singled 10 WT hermaphrodite progeny (*nuc-1*  
 10 homozygous,  $\frac{1}{2}$  heterozygous *gun*)  
 - singled 40 WT hermaphrodite progeny (1/8 homozygous *gun*)  
 - stain strains with BCECF-AM  
 - retested positives with BCECF-AM and finally 1 was  
 15 selected and kept

Table 6: Strains derived from *gun* mutations

	<i>gun</i>	<i>unc-31; gun</i>		<i>unc-31; gun</i>		<i>+</i> ; <i>gun</i>			<i>gun; nuc-1</i>
	original isolate	backcrossed (1x)		outcrossed (1x)		3x b.c.		from 3x b.c.	
	allele number	isolation number	strain number	isolation number	strain number	isolation number	strain number	strain number	strain number
20	bg77	31.4	UG 510	31.4.46.1	UG 556	31.4.34	UG 563	UG 674	UG 777
25	bg78	37.5	UG 511	37.5.46.4	UG 557	37.5.15	UG 564	UG 675	-
	bg83	10.2	UG 543	10.2.11	UG 600	10.2.21	UG 586	UG 676	-
	bg84	7.2	UG 544	7.2.10	UG 601	7.2.15	UG 589	UG 677	UG 774
	bg85	11.5	UG 545	11.5.29.2	UG 602	2x b.c.	UG 717		UG 775
	bg86	42.1	UG 546	42.1.4.5	UG 603	42.1.18	UG 587	UG 678	UG 776
30	bg87	7.1	UG 547	7.1.8.3	UG 604	7.1.22	UG 585	UG 679	-
	bg88	5.3	UG 548	5.3.9	UG 605	5.3.18	UG 584	UG 680	-
	bg89	23.4	UG 549	23.4.13.5	UG 606	23.4.3	UG 588	UG 671	-

35



SEQUENCE LISTING:

SEQ ID NO: 1 complete sequence of pGN1

5 SEQ ID NO: 2 complete sequence of pGN8

SEQ ID NO: 3 complete sequence of pGN29

SEQ ID NO: 4 complete sequence of pGN39

10 SEQ ID NO: 5 complete sequence of pGX22

SEQ ID NO: 6 complete sequence of pGX52

15 SEQ ID NO: 7 complete sequence of pGX104

SEQ ID NO: 8 complete sequence of pGZ8

SEQ ID NO: 9 primer C04H5.6F

20 SEQ ID NO: 10 primer C04H5.6R

SEQ ID NO: 11 primer K11D9.2bF

25 SEQ ID NO: 12 primer K11D9.2bR

SEQ ID NO: 13 primer Y57G11C.15F

SEQ ID NO: 14 primer Y57G11C.15R

30 SEQ ID NO: 15 primer T25G3.2F

SEQ ID NO: 16 primer T25G3.2R

Claims:

1. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to  
5 said nematode worm a food organism which is capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene following ingestion of the food organism by the nematode, wherein the nematode  
10 has a non wild-type genetic background selected to provide increased sensitivity to RNA interference as compared to wild type.
2. A method as claimed in claim 1 wherein the  
15 nematode is a microscopic nematode.
3. A method as claimed in claim 2 wherein the nematode is from the genus *Caenorhabditis*.
- 20 4. A method as claimed in claim 3 wherein the nematode is *C. elegans*.
5. A method as claimed in any one of claims 1 to 4 wherein the nematode has a mutant genetic  
25 background.
6. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits reduced activity of one or more nucleases compared to wild  
30 type.
7. A method as claimed in claim 6 wherein the nematode is *C. elegans* strain *nuc-1*.
- 35 8. A method as claimed in claim 5 wherein the nematode is a mutant strain which exhibits increased

gut uptake compared to wild type.

9. A method as claimed in claim 8 wherein the nematode is mutant *C. elegans* strain bg85.

5

10. A method as claimed in claim 5 wherein the nematode is a mutant strain having at least one mutation which results in reduced nuclease activity compared to wild type and at least one mutation which results in increased gut uptake compared to wild type.

10

11. A method as claimed in claim 10 wherein the nematode is a mutant *C. elegans* strain having the *nuc-1* mutation and the bg85 mutation.

15

12. A method as claimed in any one of the preceding claims wherein the food organism has been engineered to express a double-stranded RNA.

20

13. A method as claimed in any one of the preceding claims wherein the food organism is a bacterium.

25

14. A method as claimed in claim 13 wherein the food organism is *E. coli*.

30

15. A method as claimed in any one of the preceding claims wherein the food organism has been genetically modified to express a double-stranded RNA having a nucleotide sequence substantially identical to a portion of said target gene.

35

16. A method as claimed in claim 15 wherein the food organism contains a DNA vector, the vector comprising a promoter or promoters orientated relative to a DNA sequence such that they are capable of

initiating transcription of said DNA sequence to RNA capable of forming a double-stranded structure upon binding of an appropriate RNA polymerase to said promoter or promoters.

5

17. A method as claimed in claim 25 wherein the vector comprises two promoters flanking the DNA sequence.

10

18. A method as claimed in claim 26 wherein the two promoters are identical.

15

19. A method as claimed in claim 25 wherein the vector comprises a single promoter and further comprises said DNA sequence in a sense and an antisense orientation relative to said promoter.

20

20. A method as claimed in any one of claims 16 to 20 wherein the nematode or the food organism is adapted to express an RNA polymerase capable of initiating transcription from said promoter or promoters.

25

21. A method as claimed in any one of claims 16 to 20 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

30

22. A method as claimed in any one of claims 1 to 21 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

35

23. A method of inhibiting expression of a target gene in a nematode worm comprising feeding to said nematode worm a food organism capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a

portion of said target gene following ingestion of the food organism by the nematode, wherein the food organism carries a modification selected to provide increased expression or persistence of the doubled-stranded RNA compared to a food organism which does not carry the modification.

24. A method as claimed in claim 23 wherein the food organism is a bacterium.

25. A method as claimed in claim 24 wherein the bacterium is an *E. coli* strain.

26. A method as claimed in claim 25 wherein the *E. coli* strain is an RNase III minus strain or any other RNase negative strain.

27. A method as claimed in any one of claims 23 to 26 wherein the step of feeding said food organism to said nematode worm is carried out in liquid culture.

28. A method of inhibiting expression of a target gene in a nematode worm comprising introduction of a DNA capable of producing a double-stranded RNA structure having a nucleotide sequence substantially identical to a portion of said target gene in said nematode, wherein the nematode is one which exhibits increased gut uptake compared to wild type.

29. A method as claimed in claim 28 wherein the nematode is a microscopic nematode.

30. A method as claimed in claim 29 wherein the nematode is from the genus *Caenorhabditis*.

31. A method as claimed in claim 30 wherein the

nematode is *C. elegans*.

32. A method as claimed in any one of claims 28  
to 31 wherein the nematode has a mutant genetic  
5 background.

33. A method as claimed in claim 32 wherein the  
nematode is mutant *C. elegans* strain bg85.

10 34. A method as claimed in any one of claims 28  
to 33 wherein the DNA capable of producing a double-  
stranded RNA structure is a vector comprising a  
promoter or promoters orientated relative to a DNA  
sequence such that they are capable of initiating  
15 transcription of said DNA sequence to RNA capable of  
forming a double-stranded structure upon binding of an  
appropriate RNA polymerase to said promoter or  
promoters.

20 35. A method as claimed in claim 34 wherein the  
vector comprises two promoters flanking the DNA  
sequence.

25 36. A method as claimed in claim 35 wherein the  
two promoters are identical.

30 37. A method as claimed in claim 34 wherein the  
vector comprises a single promoter and further  
comprises said DNA sequence in a sense and an  
antisense orientation relative to said promoter.

35 38. A method as claimed in any one of claims 34  
to 37 wherein the nematode is adapted to express an  
RNA polymerase capable of initiating transcription  
from said promoter or promoters.

39. A method as claimed in any one of claims 34

to 38 wherein the RNA polymerase is T7, T3 or SP6 polymerase.

FIG. 1






FIG. 2.




FIG. 3.




FIG. 4.




FIG. 5.




FIG. 6.




FIG. 7.




FIG. 8.




FIG. 9.




FIG. 10.






FIG. 11.





FIG. 12.



1  
SEQUENCE LISTING

&lt;110&gt; DEVGEN NV

&lt;120&gt; IMPROVEMENTS RELATING TO DOUBLE-STRANDED RNA INHIBITION

&lt;130&gt; SCB/53711/001

&lt;140&gt;

&lt;141&gt;

&lt;160&gt; 14

&lt;170&gt; PatentIn Ver. 2.0

&lt;210&gt; 1

&lt;211&gt; 3216

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Plasmid pGN1

&lt;400&gt; 1

gagtgcacca	tatgcggtgt	gaaataccgc	acagatgcgt	aaggagaaaa	taccgcatca	60
ggcgaaattg	taaacgttaa	tattttggtt	aaattcgcgt	taaatatttg	ttaaatcagc	120
tcatttttta	accaataggc	cgaaatcggc	aaaatccctt	ataaatcaaa	agaatagacc	180
gagataggtg	tgagtgttgt	tccagtttgg	aacaagagtc	cactattaaa	gaacgtggac	240
tccaacgtca	aagggcgaaa	aaccgtctat	cagggcgatg	gccactacg	tgaaccatca	300
cccaaatcaa	gttttttgcg	gtcaggtgtc	cgtaaagctc	taaatcggaa	ccctaaaggg	360
agccccgat	ttagagcttg	acggggaaag	ccggcgaaag	tggcgagaaa	ggaaggggaag	420
aaagcgaaa	gagcgggcgc	tagggcgctg	gcaagtgtag	cggtcacgct	gcgcgtaacc	480
accacaccgc	ccgcgcttaa	tgcgcgcgta	cagggcgcg	ccattcgcca	ttcaggctgc	540
gcaactgttg	ggaagggcga	tcggtgcggg	cctcttcgct	attacgccag	ctggcgaaag	600
gggatgtg	tgcaaggcga	ttaagttggg	taacgccagg	gttttcccag	tcacgacgtt	660
gtaaaacgac	ggccagtga	ttgtaatacg	actcactata	gggcgaattc	gagctcggtg	720
cccggggatc	ctctagagtc	gaaagcttct	cgccctatag	tgagtcgtat	tacagcttga	780
gtattctata	gtgtcaccta	aatagcttgg	cgtaatcatg	gtcatagctg	tttcctgtgt	840
gaaattgtta	tccgctcaca	attccacaca	acatacagag	cgggaagcata	aagtgtaaag	900
cctggggtgc	ctaatagtgt	agctaactca	cattaattgc	gttgcgctca	ctgcccgtt	960
tccagtcggg	aaacctgtcg	tgccagctgc	attaatgaat	cggccaacgc	gcggggagag	1020
gcggtttg	tattgggcgc	tcttcgcgtt	cctcgctcac	tgaactcgctg	cgctcggtcg	1080
ttcggtcg	gcgagcggtg	tcagctcact	caaaggcggt	aatacgggta	tccacagaat	1140
caggggataa	cgcaggaaa	aacatgtgag	caaaaggcca	gcaaaaggcc	aggaaccgta	1200
aaaaggccgc	gttgctggcg	tttttcgata	ggctccgccc	ccctgacgag	catcacaata	1260
atcgacgtc	aagtcagagg	tggcgaaacc	cgacaggact	ataaagatac	caggcggttc	1320
cccctggaag	ctccctcg	cgctctcctg	ttccgaccct	gcccgttacc	ggataacctg	1380
ccgcctttct	cccttcggga	agcgtggcgc	tttctcatag	ctcacgctgt	aggtatctca	1440
gttcggtgta	ggtcggttcg	tccaagctgg	gctgtgtgca	cgaaccccc	gttcagccc	1500
accgctgcgc	cttatccggt	aactatcg	ttgagccaa	cccggtaaga	cacgacttat	1560
cgccactggc	agcagccact	ggtaacagga	ttagcagagc	gaggtatgta	ggcggtgcta	1620
cagagttctt	gaagtgttgg	cctaactacg	gtacactag	aaggacagta	tttggtatct	1680
gcgctctgct	gaagccagtt	accttcggaa	aaagagttgg	tagctcttga	tccggcaaac	1740
aaaccaccgc	tggtagcgg	ggtttttttg	tttgcaagca	gcagattacg	cgcagaaaaa	1800
aaggatctca	agaagatcct	ttgatctttt	ctacggggtc	tgacgctcag	tggaaacgaa	1860
actcacgtta	agggattttg	gtcatgagat	tatcaaaaag	gatcttcacc	tagatccttt	1920
taaattaaaa	atgaagtttt	aatcaatct	aaagtatata	tgagtaaact	tggtctgaca	1980

```

gttaccaatg cttaatcagt gaggcaccta tctcagcgat ctgtctatctt cgttcatcca 2040
tagttgcctg actccccgtc gtgtagataa ctacgatacg ggaggggctta ccatctggcc 2100
ccagtgcctg aatgataccg cgagacccac gctcaccggc tccagattta tcagcaataa 2160
accagccagc cggaagggcc gagcgagaa gtggtcctgc aactttatcc gcctccatcc 2220
agtctattaa ttgttgccgg gaagctagag taagtagttc gccagttaat agtttgcgca 2280
acgttgcttg cattgctaca ggcatcgtgg tgtcacgctc gtcgtttggt atggcttcat 2340
tcagctccgg ttcccaacga tcaaggcgag ttacatgac ccccatgttg tgcaaaaaag 2400
cggttagctc cttcggtcct ccgatcgttg tcagaagtaa gttggccgca gtgttatcac 2460
tcagtgttat ggcagcactg cataattctc ttactgtcat gccatccgta agatgctttt 2520
ctgtgactgg tgagtactca accaagtcac tctgagaata ccgcgcccg cgaccgagtt 2580
gctcttgccc ggcgtcaata cgggataata gtgtatgaca tagcagaact ttaaaagtgc 2640
tcatcatggg aaaacgttct cggggcgaa aactctcaag gatcttaccg ctgttgagat 2700
ccagtccgat gtaaccact cgtgaccca actgatcttc agcatctttt actttcacca 2760
gcgtttctgg gtgagcaaaa acaggaaggc aaaatgccgc aaaaaaggga ataaggcgca 2820
cacggaaatg ttgaatactc atactcttcc tttttcaata ttattgaagc atttatcagg 2880
gttattgtct catgagcgga tacatatttg aatgtattta gaaaaataaa caaatagggg 2940
ttccgcgcac atttcccgca aaagtgcac ctgacgtcta agaaaccatt attatcatga 3000
cattaacctc taaaaatagg cgtatcacga ggcccttcg tctcgcgctg ttcggtgatg 3060
acggtgaaaa cctctgacac atgcagctcc cggagacggt cacagcttgt ctgtaagcgg 3120
atgccgggag cagacaagcc cgtcagggcg cgtcagcggt tgttgccggg tgctggggct 3180
ggcttaacta tgcggcatca gacgagattg tactga 3216

```

&lt;210&gt; 2

&lt;211&gt; 4620

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Plasmid pGN8

&lt;400&gt; 2

```

gatccgaatc tccatgtctg ttaacagcct tgacacggaa tttatattca tgcccttgag 60
tcaaactcgtc aacgtggaag ttggtatcct tgctctctcc gcaagcagtc catctgccag 120
tggcagcatc ttgcttttca atgacatagt gactgatttc agctcctcca tcatctctg 180
gttccctcca tgcaagatca catccatcct tgacaatatt agtgacatcg agagggtccac 240
gtgggcttga tggatgatca agaacagtaa ccttcacttc agcagtgtca gttccattct 300
cgttctctgc cttgatgata taggttcctg tatccgaacg caaagctctc ttcacatgga 360
atttagtctt gccgtcttca ttgttcaact tcatacgatc atcagattcg actggtgttc 420
cttcgaaagt ccaagtaatt gttaggattg gttcaccact gactggaatg ttcaatgaga 480
agtcttgctc agccttgacc ttgatttctt gaatcgagtt acgatcgatg actgggtgga 540
ctataattta attcaatgat tattagtaat tgatttagac tcttaccatt tctagccttt 600
gcaacagctg atgctgaatc agatggatct cccaatcctg ccttggtctt ggcacggatt 660
ctgaattcgt actttgatcc ttcttgaga tttccaacag tagcattcgt ttgtccagct 720
ggaacatgag caacgtcatt ccagaatggc gagaactcgt ccttcacttc aacaacgtat 780
tctctgattg gagcaccacc gtcggttgct ggtggcttcc attcaagtc aacatgatcc 840
ttatcccaat cagtaatttc aggagcattt gtctttcctg gcttgctaaa tggatctttg 900
gcaagtgtgg ttccgaaggt ctccaatgga tcggactctc cttcagcatt gacggcagcg 960
acacggaact gaaaatcaaa atgttgtagg caattgagtt caagattaaa aaattctcac 1020
tttatattca tgtccaggaa taagaccgtc aacaacagct gtagtcttat ctccagcgac 1080
ctttgcagct ggaaccatc ttccacttgc agtatcgta ttttcgatca catagttttc 1140
aattggaata cctccatcat catctggtgc acgccaatc aaagtgcac gatcaccatg 1200
aacatcggaa acatctaatt gaccatttgg agaagtggc ttgtctgaaa atttaaaata 1260
taaccaaat aattgaagaa aactaatgct caccaataac attgatctta acagttgctt 1320
catcttctcc atttgcatg acagcttga tagtgaaagt tccactgtct ccacgttcca 1380
tttgcttca aaccagcttt gattgggtatt ctgggttacc aagcttctcg ccttatagtg 1440
agtcgtatta cagcttgagt attctatagt gtcacctaaa tagcttgccg taatcatggt 1500
catagctgtt tctgtgtgta aattgttate cgctcacaat tccacacaac atacgagccg 1560
gaagcataaa gtgtaaagcc tggggtgcct aatgagttag ctaactcaca ttaattgcgt 1620

```

```

tgcgctcact gcccgctttc cagtcgggaa acctgtcgtg ccagctgcat taatgaatcg 1680
gccaacgcgc ggggagaggc gggttgcgta ttgggcgctc ttccgcttcc tcgctcactg 1740
actcgctgcg ctccggtcggt cggctgcggc gagcgggtatc agctcactca aaggcggtaa 1800
tacggttatc cacagaatca ggggataacg caggaaagaa catgtgagca aaaggccagc 1860
aaaaggccag gaaccgtaaa aaggccgcgt tgctggcggt ttccgatagg ctccgcccc 1920
ctgacgagca tcacaaaaat cgacgctcaa gtcagagggt gcgaaacccg acaggactat 1980
aaagatacca ggcgtttccc cctggaagct ccctcgtgcg ctctcctgtt ccgaccctgc 2040
cgcttaccgg atacctgtcc gcctttctcc ctccgggaag cgtggcgctt tctcatagct 2100
cacgctgtag gtatctcagt tcggtgtagg tcgttcgctc caagctgggc tgtgtgcacg 2160
aacccccgt tcagcccgac cgctgcgcct tatccggtaa ctatcgtctt gagtccaacc 2220
cggtaagaca cgacttatcg ccactggcag cagccactgg taacaggatt agcagagcga 2280
ggatgtagg cggtgctaca gagtcttga agtgggtggc taactacggc tacactagaa 2340
ggacagtatt tggatatctgc gctctgctga agccagttac ctccgaaaaa agagtggta 2400
gctcttgatc cggcaaacaa accaccgtg gtagcgggtg tttttttgtt tgcaagcagc 2460
agattacgcg cagaaaaaaa ggatctcaag aagatccctt gatcttttct acggggtctg 2520
acgctcagtg gaacgaaaaa tcacgttaag ggattttgtt catgagatta tcaaaaagga 2580
tcttcacctg gatcctttta aattaaaaat gaagttttta atcaatctaa agtatatatg 2640
agtaaacctt gctgacagt taccaatgct taatcagtga ggcacctatc tcagcgatct 2700
gtctatttctg ttcattccata gttgcctgac tcccgcgtcg gtagataact acgatacggg 2760
agggcttacc atctggcccc agtgcgcaa tgataccgcg agaccacgc tcaccggctc 2820
cagatttatc agcaataaac cagccagccg gaagggccga gcgcagaagt ggtcctgcaa 2880
ctttatccgc ctccatccag tctattaatt gttgccggga agctagagta agtagttcgc 2940
cagtttaacg tttgcgcaac gttgttgga catcgtgggt tcacgctcgt 3000
cgtttggtat ggcttcatc agtccgggt cccaacgatc aaggcgagtt acatgatccc 3060
ccatgttgtg caaaaaagcg gttagctcct tcggctctcc gatcgttgtc agaagtaagt 3120
tggccgcagt gttatcactc atggttatgg cagcactgca taattctctt actgtcatgc 3180
catccgtaag atgcttttct gtgactgggt agtactcaac caagtcattc tgagaatacc 3240
gcgcccggcg accgagttgc tcttgcggcg cgtcaatacg ggataatagt gtatgacata 3300
gcagtaatatg aaaagtgtc atcattggaa aacgttcttc ggggcgaaaa ctctcaagga 3360
tcttaccgct gttgagatcc agttcgatgt aaccactcgc tgcacccaac tgatcttcag 3420
catcttttac tttcaccagc gtttctgggt gagcaaaaac aggaaggcaa aatgccgcaa 3480
aaaagggaat aaggcgacaa cggaatgtt gaatactcat actcttcctt tttcaatatt 3540
attgaagcat ttatcagggt tattgtctca tgagcggata catatttgaa tgtatttaga 3600
aaaataaaca aatagggtt ccgcgcacat tccccgaaa agtgccacct gacgtctaag 3660
aaaccattat tatcatgaca ttaacctata aaaataggcg tatcacgagg ccctttcgtc 3720
tcgcgcggtt cggtgatgac ggtgaaaacc tctgacacat gcagctcccg gagacggta 3780
cagcttgtct gtaagcggat gccgggagca gacaagccc tcagggcgcg tcagcgggtg 3840
ttggcgggtg tcggggctgg cttaactatg cggcatcaga gcagattgta ctgagagtgc 3900
accatattgc gtgtgaaata ccgcacagat gcgtaaggag aaaataaccgc atcaggcgaa 3960
attgtaaacg ttaataattt gttaaaatt gcgttaataa tttgttaaat cagctcattt 4020
tttaaccaat aggcggaaat cggcaaaatc ccttataaat caaaagaata gaccgagata 4080
gggttgagtg ttgttccagt ttggaacaag agtccactat taaagaacgt ggactccaac 4140
gtcaaagggc gaaaaaccgt ctatcagggc gatggccac tacgtgaacc atcaccacaa 4200
tcaagttttt tgcggctgag gtgccgtaaa gctctaaatc ggaaccctaa agggagcccc 4260
cgatttagag cttgacgggg aaagccggcg aacgtggcga gaaagggaag gaagaaagcg 4320
aaaggagcgg gcgctagggc gctggcaagt gtagcggtca cgctgcgcgt aaccaccaca 4380
ccgcgcgcgc ttaatgcgcc gctacagggc gcgtccattc gccattcagg ctgcgcaact 4440
gttgggaagg gcgcatcgtg cgggcctctt cgctattacg ccagctggcg aaagggggat 4500
gtgctgcaag gcgattaagt tgggtaacgc cagggttttc ccagtcacga cgttgtaaaa 4560
cgacggccag tgaattgtaa tacgactcac tataggcgga attcgagctc ggtacccggg 4620

```

&lt;210&gt; 3

&lt;211&gt; 4756

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Plasmid pGX22

&lt;400&gt; 3

tgctcagaga	gtttctcaac	gaacccgatt	tggttagtta	taggtaattt	ttagaacatt	60
tacaaaaaca	gcaaaaaaac	caaacattca	ggatttttgt	ttttaattaa	gaaaaaaatc	120
gatcgctctt	aaattttaat	caatacttcg	aataaaacca	aaaaaaaacg	aaaaaaaatc	180
ctgtttccag	tgtaatgatg	attgacgagg	ctcacgaacg	tactctacac	acggatattc	240
tattcggttt	agtcaaagat	attgcaagat	tccgaaagga	tttgaagctt	ctcatctctt	300
ctgcaacact	tgacgctgaa	aagttctcca	gtttcttcga	cgacgctccg	attttccgaa	360
ttccgggacg	cagattcccg	gtggacattt	actatacaca	ggctcccga	gcggactacg	420
tcgacgcggc	tatcgtcaca	attatgcaga	ttcacttgac	ccagccactt	ccggcgata	480
ttttggtatt	tctgactggt	caggaagaaa	tcgaaactgt	acaggaagca	cttatggaac	540
ggtcgaaagc	actgggatcg	aagattaagg	agcttattcc	gctgccggtt	tatgcgaatt	600
tgcccagtga	tttgcaggcg	aagattttcg	agccaacgcc	gaaagatgcg	agaaaggtag	660
atttttctta	caaatttttt	ccaaaaaaa	atccgagaaa	aatctacaaa	atttcaggca	720
aaaactgttt	catttttatc	ctaactagtt	ttttagcaaa	cgtttagatt	taacaaaact	780
gaacaaattt	gaagttttcc	aatttaaaaa	ataaatgttt	cggaaagttt	attgaaaaat	840
ctgaaattgc	tatctctcgc	tatctgcaaa	aaaaacactt	taaaaaatgc	tctgttcttt	900
gaaaatttct	aaactgaaaa	atttgaaatt	tctgaaaatt	gtgataattt	tataaaattt	960
tatagaaaat	gtaagcattc	cagaaaaata	tcaaaaattt	cgagaaaatt	ctgaaaaaat	1020
ccagaaatat	taacagaaaa	aaaatctttt	gaaacatctg	aaaattaaaa	taaattgaat	1080
ttacattttt	ttttttggga	tttccttaaa	atcactatga	atttaccact	aaattttttg	1140
caaaaaatta	tttttttaat	ttcaaaagaa	aagcaaaagaa	ttttaaaata	tcaaaaagtc	1200
caaatttggt	tcggtgaaatt	tttaaaataa	cattttcaag	ataattttta	gttaatcaaa	1260
acattccacg	catttctagt	ttcccaaatt	tctctaaatt	tcaggtggtc	ctagcaacta	1320
acattgccag	cacaatggat	ctcgagggat	cttccatacc	taccagttct	gcgcctgcag	1380
gtcgcgccg	cgactctcta	gacgcgtaag	cttactagca	taaccctctg	gggcctctaa	1440
acgggtcttg	aggggttttt	tgagcttctc	gccctatagt	gagtcgtatt	acagcttgag	1500
tattctatag	tgtcacctaa	atagcttggc	gtaatcatgg	tcatactgtg	ttcctgtgtg	1560
aaattgttat	ccgctcacaa	ttccacacaa	catacgagcc	ggaagcataa	agtgtaaagc	1620
ctgggggtgcc	taatgagtga	gctaactcac	attaattgcg	ttgcgctcac	tgcccgtttt	1680
ccagtcggga	aaactgtcgt	gccagctgca	ttaatgaatc	ggccaacgcg	cggggagagg	1740
cggtttgctg	attggggcgt	cttcgccttc	ctcgctcact	gactcgctgc	gctcggctcg	1800
tcggctgcgg	cgagcgggat	cagctcactc	aaaggcggta	atacggttat	ccacagaatc	1860
aggggataac	gcaggaaaaga	acatgtgagc	aaaaggccag	caaaaggcca	ggaaccgtaa	1920
aaaggccgcg	ttgctggcgt	ttttcgatag	gctccgcccc	cctgacgagc	atcacaaaaa	1980
tcgacgctca	agtcagaggt	ggcgaaaccc	gacaggacta	taaagatacc	aggcgtttcc	2040
ccctggaagc	tcctctcgtg	gctctcctgt	tccgaccctg	ccgcttaccc	gatacctgtc	2100
cgcctttctc	ccttcgggaa	gcgtggcgct	ttctcatagc	tcacgctgta	ggtatctcag	2160
ttcggtgtag	tctgcttcgt	ccaagctggg	ctgtgtgcac	gaaccccccg	ttcagcccca	2220
ccgctgcgcc	ttatccggta	actatcgtct	tgagccaac	ccggtaagac	acgacttata	2280
gccactggca	gcagccactg	gtaacaggat	tagcagagcg	aggatgtag	gcggtgctac	2340
agagttcttg	aagtgggtgg	ctaactacgg	ctacactaga	aggacagtat	ttggtatctg	2400
cgctctgctg	aagccagtta	ccttcggaaa	aagagttggt	agctcttgat	ccggcaaaaa	2460
aaccaccgct	ggtagcgggt	gtttttttgt	ttgcaagcag	cagattacgc	gcagaaaaaa	2520
aggatctcaa	gaagatcctt	tgatcttttc	tacggggtct	gacgctcagt	ggaacgaaaa	2580
ctcacgttaa	gggatttttg	tcatgagatt	atcaaaaagg	atcttcacct	agatcctttt	2640
aaattaaaaa	tgaagtttta	aatcaatcta	aagtatatat	gagtaaaact	ggtctgacag	2700
ttaccaatgc	ttaatcagtg	aggcacctat	ctcagcgatc	tgtctatttc	gttcatccat	2760
agttgcctga	ctccccgtcg	tgtagataac	tacgatacgg	gagggcttac	catctggccc	2820
cagtgtctga	atgataccgc	gagaccacg	ctcaccggct	ccagatttat	cagcaataaa	2880
ccagccagcc	ggaaggggcg	agcgagaag	tggtcctgca	actttatccg	cctccatcca	2940
gtctattaat	gtttgccggg	aagctagagt	aagtagttcg	ccagtttaata	gtttgcgcaa	3000
cgttgtttgg	attgctacag	gcacgttggt	gtcacgctcg	tcgtttggta	tggttctcatt	3060
cagctccggt	tccaacgat	caaggcgagt	tacatgatcc	cccatgttgt	gcaaaaaagc	3120
ggttagctcc	ttcggtcctc	cgatcgttgt	cagaagtaag	ttggccgcag	tgttatcact	3180
catggttatg	gcagcactgc	ataattctct	tactgtcatg	ccatccgtaa	gatgcttttc	3240
tgtgactggt	gagtgactca	ccaagtcatt	ctgagaatac	cgcgccgggc	gaccgagttg	3300
ctcttgcccg	gcgtcaatac	gggataatag	tgtatgacat	agcagaactt	taaaagtgtc	3360

5

```

catcattgga aaacgtttott cggggcgaaa actctcaagg atcttaccgc tgttgagatc 3420
cagttcgaatg taaccactc gtgcacccaa ctgatcttca gcatctttta ctttcaccag 3480
cgtttctggg tgagcaaaaa caggaaggca aaatgccgca aaaaaggga taaggcgac 3540
acggaaatgt tgaatactca tactcttctt ttttcaatat tattgaagca tttatcaggg 3600
ttattgtctc atgagcggat acatatattga atgtatttag aaaaataaac aaataggggt 3660
tccgcgcaca ttcccccga aagtgccacc tgacgtctaa gaaaccatta ttatcatgac 3720
attaacctat aaaaataggc gtatcacgag gccctttcgt ctgcgcggtt tcggtgatga 3780
cgggtgaaaac ctctgacaca tgcagctccc ggagacggtc acagcttgct tgtaagcgga 3840
tgccgggagc agacaagccc gtcaggggcg gtcagcgggt gttggcgggt gtcggggctg 3900
gcttaactat gcggcatcag agcagattgt actgagagt caccatatgc ggtgtgaaat 3960
accgcacaga tgcgtaagga gaaaataccg catcaggcga aattgtaaac gttaatat 4020
tggtaaaatt cgcgttaaat atttgtaaaa tcagctcatt ttttaacaa taggccgaaa 4080
tcggcaaaat cccttataaa tcaaaagaat agaccgagat agggttgagt gttgttccag 4140
tttggaacaa gagtccacta ttaagaacg tggactcaa cgtcaaagg cgaaaaaccg 4200
tctatcaggc cgatggccca ctacgtgaac catcacccaa atcaagtttt ttgcggctga 4260
ggtgccgtaa agctctaaat cggaacccta aaggagccc ccgatttaga gcttgacggg 4320
gaaagccggc gaacgtggcg agaaaggagc ggaagaaagc gaaaggagc ggcgctaggg 4380
cgctggcaag tgtagcggtc acgctgcgcg taaccaccac acccgccgcg cttaatgcgc 4440
cgctacaggc cgcgtccatt cgccattcag gctgcgcaac tgttggaag ggcgatcggt 4500
gcgggcctct tcgctattac gccagctggc gaaaggggga tgtgctgcaa ggcgattaag 4560
ttgggtaaog ccagggtttt cccagtcacg acgttgtaaa acgacggcca gtgaattgta 4620
atacgactca ctatagggcg aattcaaaaa acccctcaag acccgtttag aggccccaag 4680
gggttatgct agtgaattct gcagggtacc cggggatcct ctagagatcc ctcgacctcg 4740
agatccattg tgctgg

```

&lt;210&gt; 4

&lt;211&gt; 4643

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Plasmid pGX52

&lt;400&gt; 4

```

gagtgcacca tatgcgggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca 60
ggcgaaattg taaacgttaa tattttgtta aaattcgcgt taaatatttg ttaaatcagc 120
tcatttttta accaataggc cgaaatcggc aaaatccctt ataatcaaa agaataagacc 180
gagatagggt tgagtgttgt tccagtttg aacaagagtc cactattaaa gaacgtggac 240
tccaacgtca aaggcgaaa aaccgtctat cagggcgatg gccactacg tgaacctca 300
cccaaatcaa gttttttgcg gtcgaggtgc cgtaaagctc taaatcgaa ccctaaaggg 360
agccccgat ttagagcttg acggggaag cggcgaaagc tggcgagaaa ggaagggaag 420
aaagcgaaag gagcgggcgc tagggcgctg gcaagtgtag cggtcacgct gcgcgtaacc 480
accacaccgc ccgcgcttaa tgcgcgcta cagggcgct ccattcgcca ttcaggctgc 540
gcaactgttg ggaaggcgga tcggtgcgg cctcttcgct attacgccag ctggcgaaag 600
ggggatgtgc tgcaaggcga ttaagttgg taacgccagg gttttccag tcacgacgtt 660
gtaaaacgac gccagtgaa ttgtaatag actcactata gggcgaattc aaaaaacccc 720
tcaagaccgc ttagaggcc ccaaggggtt atgctagtga attctgcagg gtacccgggg 780
atcctctaga gatccctcga cctcgagatc cattgtgctg gcagccgatc tccgtcttgt 840
gaagatctac tccaccacca tccgtatcga tcagtccatc ctcaccggag aatctgtgtc 900
tggtatcaag cacaccgact ctgtgccaga tccacgcgct gtaaccagg acaagaagaa 960
ttgtctgttc tcgggaacca atgtcgcac tggaaaggct cgtggaatcg tcttcggaac 1020
cggattgacc actgaaatcg gaaagatccg taccgaaatg gctgagaccg agaatgagaa 1080
gacaccactt caacagaagt tggacgaatt cggagagcaa ctttccaagg ttatctctgt 1140
tatttgcgtt gctgtttgg ctatcaacat tggacatttc aacgatccag ctacggtgg 1200
atcatgggtt aaggagcaa tctactact caaaatcgcc gttgctcttg ccgtcgctgc 1260
tattccagaa ggaactccag ctgtcatcac cagtgccct gccctcgaa ctcgccgtat 1320
ggccaagaag aacgctattg taagatccct tccatccgtc gaaactcttg gatgcacatc 1380
tggtatctgc tctgacaaga ctggaactct caccaccaac cagatgtctg tgtcaaagat 1440

```

gttcacgcgt	ggacaagctt	ctggagacaa	catcaacttc	accgagttcg	ccatctccgg	1500
atccacctac	gagccagtcg	gaaaggtttc	caccaatgga	cgtgaaatca	acccagctgc	1560
tggagaattc	gaatcactca	ccgagttggc	catgatctgc	gctatgtgca	atgattcatc	1620
tgttgattac	aatgagacca	agaagatcta	cgagaaagtc	ggagaagcca	ctgaaactgc	1680
tcttatcggt	cttgctgaga	agatgaatgt	tttcggaacc	tcgaaagccg	gactttcacc	1740
aaaggagctc	ggaggagttt	gcaaccgtgt	catccaaaca	aaatggaaga	aggagttcac	1800
actcgagttc	tcccgtgata	gtaaataccat	gtccgcctac	tgcttccag	cttccggagg	1860
atctggagcc	aagatgttcg	tgaaggagc	cccagaagga	gttctcggaa	gatgcaccca	1920
cgtcagagtt	aacggacaaa	aggttccact	cacctctgcc	atgactcaga	agattgttga	1980
ccaatgcgtg	caatacggaa	ccggaagaga	tacccttcgt	tgtcttgccc	tcggccagca	2040
caatggatct	cgaggatctc	tccataccta	ccagttctgc	gcctgcaggt	cgcggcccg	2100
actctctaga	ctcgtaagct	tactagcata	accccttggg	gcctctaaac	gggtcttgag	2160
gggttttttg	agcttctcgc	cctatagtga	gtcgtattac	agcttgagta	ttctatagt	2220
tcacctaaat	agcttggcgt	aatcatggtc	atagctgttt	cctgtgtgaa	attgttatcc	2280
gctcacaatt	ccacacaaca	tacgagccgg	aagcataaag	tgtaaagcct	ggggtgccta	2340
atgagtgaac	taactcacat	taattgcgtt	gcgctcactg	cccgctttcc	agtcgggaaa	2400
cctgtcgtgc	cagctgcatt	aatgaatcgg	ccaacgcgcg	gggagaggcg	gtttgcgtat	2460
tggcgctctc	tccgcttcc	cgctcactga	ctcgtcgcgc	tcggctcgtc	ggctgcggcg	2520
agcggatatca	gctcactcaa	aggcggtaat	acggttatcc	acagaatcag	gggataacgc	2580
aggaaagaac	atgtgagcaa	aaggccagca	aaaggccagg	aaccgtaaaa	aggccgcggt	2640
gctggcggtt	ttcgatagga	tccgcccccc	tgacgagcat	cacaaaaatc	gacgctcaag	2700
tcagagggtg	cgaaacccga	caggactata	aagataccag	gcgtttcccc	ctggaagctc	2760
cctcgtgcgc	tctcctgttc	cgaccctgcc	gcttaccgga	tacctgtccg	cctttctccc	2820
ttcgggaagc	gtggcgcttt	ctcatagctc	acgctgtagg	tatctcagtt	cgggtgtaggt	2880
cgttcgctcc	aagctgggct	gtgtgcacga	acccccggtt	cagcccgacc	gctgcgcctt	2940
atccggtaac	tatcgtcttg	agtccaaccc	ggtaagacac	gacttatcgc	cactggcagc	3000
agccactggt	aacaggatta	gcagagcgag	gtatgtagcc	gggtgctacag	agttcttgaa	3060
gtggtggcct	aactacggct	acactagaag	gacagtattt	ggatatctgc	ctctgctgaa	3120
gccaggttac	ttcggaaaaa	gagttggtag	ctcttgatcc	ggcaaacaaa	ccaccgctgg	3180
tagcgggtgt	ttttttgttt	gcaagcagca	gattacgcgc	agaaaaaaag	gatctcaaga	3240
agatcctttg	atcttttcta	cggggtctga	cgctcagtg	aacgaaaact	cacgttaagg	3300
gattttgggt	atgagattat	caaaaaggat	cttcacctag	atccttttaa	attaaaaatg	3360
aagttttaaa	tcaatctaaa	gtatatatga	gtaaacttgg	tctgacagtt	accaatgctt	3420
aatcagtgag	gcacctatct	cagcgatctg	tctatttcgt	tcattccatag	ttgcctgact	3480
ccccgtcgtg	tagataacta	cgatacggga	gggcttacca	tctggcccca	gtgctgcaat	3540
gataccgcga	gaccacgcct	caccggctcc	agatttatca	gcaataaacc	agccagccgg	3600
aagggccgag	cgcagaagtg	gtcctgcaac	tttatccgcc	tccatccagt	ctattaattg	3660
ttgcccggaa	gctagagtaa	gtagtccgcc	agttaaatgt	ttgcgcaacg	ttgttggtcat	3720
tgctacagga	atcgtgggtg	cacgctcgtc	gtttggtagt	gcttcattca	gctccgggtc	3780
ccaacgatca	aggcgagtta	catgatcccc	catgttgcgc	aaaaaagcgg	ttagctcctt	3840
cggctctacc	atcgtttgca	gaagtaagtt	ggccgcagtg	ttatcactca	tgggttatggc	3900
agcactgcat	aattctctta	ctgtcatgcc	atccgtaaga	tgcttttctg	tgactggtga	3960
gtactcaacc	aagtcattct	gagaataccg	cgcccgccga	ccgagttgct	cttgcccggc	4020
gtcaatacgg	gataatagt	tatgacatag	cagaacttta	aaagtgtca	tcattggaaa	4080
acgttcttcg	ggcgaaaaac	tctcaaggat	cttaccgctg	ttgagatcca	gttcgatgta	4140
acccactcgt	gcacccaact	gatcttcagc	atcttttact	ttcaccagcg	tttctgggtg	4200
agcaaaaaca	ggaaggcaaa	atgccgcaaa	aaagggaata	agggcgacac	ggaaatgttg	4260
aatactcata	ctcttccctt	ttcaatatta	ttgaagcatt	tatcagggtt	attgtctcat	4320
gagcggatac	atatttgaat	gtatttagaa	aaataaaca	ataggggttc	cgcgcacatt	4380
tccccgaaaa	gtgccacctg	acgtctaaga	aaccattatt	atcatgacat	taacctataa	4440
aaataggcgt	atcacgaggc	cctttcgtct	cgcgcgtttc	ggtgatgacg	gtgaaaacct	4500
ctgacacatg	cagctcccgg	agacggteac	agcttctctg	taagcggatg	ccgggagcag	4560
acaagccgct	cagggcgctg	cagcgggtgt	tggcgggtgt	cggggctggc	ttaaactatg	4620
ggcatcagag	cagattgtac	tga				4643

&lt;210&gt; 5

&lt;211&gt; 4454

&lt;212&gt; DNA

## &lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Plasmid pGX104

&lt;400&gt; 5

```
gagtgcacca tatgcggtgt gaaataccgc acagatgcgt aaggagaaaa taccgcatca 60
ggcgaaattg taaacgttaa tattttgtta aaattcgcgt taaatatttg ttaaatcagc 120
tcatttttta accaataggg cgaaatcggc aaaatccctt ataaatcaaa agaatagacc 180
gagatagggg tgagtgttgt tccagtttgg aacaagagtc cactattaaa gaacgtggac 240
tccaacgtca aagggcgaaa aaccgtctat cagggcgatg gcccactacg tgaaccatca 300
cccaaatcaa gttttttgcg gtcgaggtgc cgtaaagctc taaatcgga ccctaaaggg 360
agccccgat ttagagcttg acggggaaag cggcgaaacg tggcgagaaa ggaagggaag 420
aaagcgaaag gagcggggcg tagggcgctg gcaagtgtag cggtcacgct gcgcgtaacc 480
accacacccg ccgcgcttaa tgcgccgcta cagggcgcggt ccattcgcca ttcaggtcgc 540
gcaactgttg ggaagggcga tcggtgcggg cctcttcgct attacgccag ctggcgaaag 600
ggggatgtgc tgcaaggcga ttaagtggg taacgccagg gttttcccag tcacgacggt 660
gtaaaacgac ggccagtga ttgtaatac actcactata gggcgaattc aaaaaacccc 720
tcaagaccgg ttttagaggc ccaaggggtt atgctagtga attctgcagg gtacccgggg 780
atcctctaga gatccctcga cctcgagatc cattgtgctg gaccgtggtt ctcttatgga 840
gctcggaatc tcgccaatcg tcacttctgg acttatcatg caacttctcg ccggagccaa 900
gatcatcgaa gtcggagaca caccaaagga ccgtgctctt ttcaacggag ccagaaatg 960
taagccgaaa agtgtgtgtt ttcaatctct aatttttgaa cttttcagtg ttcggtatgg 1020
tcactactgt tggacaagct attgtctacg tcatgtccgg actctacgga gagccatcgg 1080
aaatcggagc tggaatctgt ctcttatcgc tcgtccaact cgttattgcc ggtctcatcg 1140
tcctccttct cgacgagctt ctccaaaagg gatatggtct cggatccgga atttctctct 1200
tcattgccac caacatctgt gaaaccattg tctggaaggc attctccccg gcaacaatga 1260
acacccgagc tggaaaccgag ttcgaaaggag ccgtcattgc tcttttccat cttcttgcca 1320
cccgctccga caaggtccgt gcccttcgtg aggttttcta ccgtcaaaac cttccaaact 1380
tgatgaactt gatggctact ttctcgttt ttgcggtggt tatctacttc caaggattcc 1440
gtgtcgacct cccaatcaag tctgccgct accgtggaca atacagcagc taccaatca 1500
agctcttcta cacctccaac attccaatca tccttcaatc tgctctcgtc tccaacctct 1560
acgttatctc tcaggtttgt tgcatctcag tagtacggtt agatgtttat ctttctctag 1620
agggtaacgt tggcggagaa attttttgag ttcatctca agtctgatgg aaaaagttaa 1680
tttttcagat gtcgcggcga aagttcggag gaaacttctt catcaacctt ctcggtacct 1740
ggtcggataa caccggatac agaagctacc caactggagg actctgctac tatctttcac 1800
caccagagtc tcttggaacac atcttcgaag acccaatcca ctgcaccagc acaatggatc 1860
tcgagggatc ttccatacct accagtctcg cgcctgcagg tcgcggcgcg gactctctag 1920
acgcgttaag ttactagcat aacccttggt ggcctctaaa cgggtcttga ggggtttttt 1980
gagcttctcg ccctatagtg agtcgtatta cagcttgagt attctatagt gtcacctaaa 2040
tagcttgccg taatcatggt catagctgtt tcctgtgtga aattgttatc cgctcacaat 2100
tccacacaac atacgagccg gaagcataaa gtgtaaagcc tggggtgcct aatgagttag 2160
ctaactcaca ttaattgctg tgcgctcact gcccgctttc cagtcgggaa acctgtcgtg 2220
ccagctgcat taatgaatcg gccaacgcgc ggggagaggg ggtttgcgta ttgggcgctc 2280
ttccgcttcc tcgctcactg actcgctgcg ctcggtcggt cggctgcggc gagcgggtatc 2340
agctcactca aaggcggtaa tacggttatc cacagaatca ggggataacg caggaaagaa 2400
catgtgagca aaaggccagc aaaaggccag gaaccgtaaa aaggccgcgt tgctggcggt 2460
tttcgatagg ctccgcccc ctgacgagca tcacaaaaat cgacgctcaa gtcagagggtg 2520
gcgaaacccg acaggactat aaagatacca ggcgtttccc cctggaagct ccctcgtgcg 2580
ctctcctgtt ccgaccctgc cgcttaccgg atacctgtcc gcctttctcc cttcggaag 2640
cgtggcgctt tctcatagct cagctgttag gtatctcagt tcggtgtagg tcgttcgctc 2700
caagctgggc tgtgtgcacg aacccccgt tcagcccgc cgtgcgcct tatccggtaa 2760
ctatcgtctt gagtccaacc cggtaaagaca cgacttatcg ccactggcag cagccactgg 2820
taacaggatt agcagagcga ggtatgtagg cgggtctaca gagttcttga agtggtggcc 2880
taactacggc tacactagaa ggacagtatt tggatctgc gctctgctga agccagttac 2940
cttcggaaaa agagttggta gctcttgatc cggcaaaaa accaccgctg gtagcggtgg 3000
tttttttgtt tgcaagcagc agattacgcg cagaaaaaaa ggatctcaag aagatccttt 3060
gatcttttct acggggtctg acgctcagtg gaacgaaaac tcacgttaag ggattttggt 3120
```



8

```

catgagatta tcaaaaagga tcttcaccta gatcctttta aattaaaaat gaagttttta 3180
atcaatctaa agtatatatg agtaaaacttg gtctgacagt taccaatgct taatcagtga 3240
ggcacctatc tcagcgatct gtctatttcg ttcacccata gttgcctgac tccccgctgt 3300
gtagataact acgatacggg agggcttacc atctggcccc agtgctgcaa tgataccgct 3360
agaccacgc tcaccggctc cagatttacc agcaataaac cagccagccg gaagggccga 3420
gcgcagaagt ggtcctgcaa ctttatccgc ctccatccag tctattaatt gttgccggga 3480
agctagagta agtagttcgc cagttaatag tttgcgcaac gttgttggca ttgctacagg 3540
catcgtgggtg tcacgctcgt cgtttggtat ggcttcattc agctccggtt cccaacgatc 3600
aaggcgagtt acatgatccc ccatgttggtg caaaaaagcg gttagctcct tcgggtcctcc 3660
gatcgtttgtc agaagtaagt tggccgcagt gttatcactc atgggttatgg cagcactgca 3720
taattctctt actgtcatgc catccgtaag atgcttttct gtgactgggt agtactcaac 3780
caagtcattc tgagaatacc gcgcccgcg accgagttgc tcttgccggg cgtcaatacg 3840
ggataaatagt gtatgacata gcagaacttt aaaagtgtc atcattggaa aacgttcttc 3900
ggggcgaaaa ctctcaagga tcttaccgct gttgagatcc agttcgatgt aaccactcg 3960
tgcacccaac tgatcttcag catcttttac tttcaccagc gtttctgggt gagcaaaaac 4020
aggaaggcaa aatgccgcaa aaaagggat aagggcgaca cggaaatgtt gaatactcat 4080
actcttctct tttcaatatt attgaagcat ttatcagggt tattgtctca tgagcgata 4140
catatttgaa tgtatttaga aaaataaaca aatagggtt ccgcgcacat tccccgaaa 4200
agtgccacct gacgtctaag aaaccattat tatcatgaca ttaacctata aaaataggcg 4260
tatcacgagg ccctttcgtc tcgcgcgttt cggtagatgc ggtgaaaacc tctgacacat 4320
gcagctcccg gagacgggtc cagcttgtct gtaagcggat gccgggagca gacaagccc 4380
tcagggcgcg tcagcgggtg ttggcgggtg tcggggctgg cttaactatg cggcatcaga 4440
gcagattgta ctga                                     4454

```

&lt;210&gt; 6

&lt;211&gt; 4701

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Description of Artificial Sequence: Plasmid pGZ18

&lt;400&gt; 6

```

accagcttt cttgtacaaa gtggtgatct ttccagcaca atggatctcg agggatcttc 60
catactacc agttctgcgc ctgcaggtcg cggccgcgac tctctagacg cgtaaagctta 120
ctagcataac cccttggggc ctctaaacgg gtcttgaggg gttttttgag cttctcgccc 180
tatagtgagt cgtattacag cttgagtatt ctatagtgtc acctaaatag cttggcgtaa 240
tcatggtcat agctgtttcc tgtgtgaaat tgttatccgc tcacaattcc acacaacata 300
cgagccggaa gcataaagtg taaagcctgg ggtgccta at gagtgagcta actcacatta 360
attgctttgc gctcactgcc cgctttccag tcgggaaacc tgcgtgcca gctgcattaa 420
tgaatcgccc aacgcgcggg gagaggcgtt ttgcgtattg ggcgctcttc cgcttccctg 480
ctcactgact cgctgcgctc ggtcgttcgg ctgcggcgag cggtatcagc tcaactcaaag 540
gcggtaatat ggttatccac agaatcaggg gataacgcag gaaagaacat gtgagcaaaa 600
ggccagcaaa aggccaggaa ccgtaaaaag gccgcgttgc tggcggtttt cgataggctc 660
cgccccctg acgagcatca caaaaaatcga cgctcaagtc agagggtggcg aaaccgcaca 720
ggactataaa gataccagge gtttccccct ggaagctccc tcgtgcgctc tctgtttccg 780
accctgcgcg ttaccggata cctgtccgcc tttctccctt cgggaagcgt ggcgctttct 840
catagctcac gctgtaggta tctcagttcg gtgtaggctg ttcgctccaa gctgggctgt 900
gtgcacgaac ccccggttca gcccgaccgc tgcgccttat ccggtactaa tcgtcttgag 960
tccaaccgg taagacacga cttatcgcca ctggcagcag ccaactgtaa caggattagc 1020
agagcgaggt atgtaggcgg tgctacagag ttcttgaagt ggtggcctaa ctacggctac 1080
actagaagga cagtatttgg tatctgcgt ctgctgaagc cagttacctt cggaaaaaga 1140
gttggtgact cttgatccgg caaacaacc accgctggta gcggtggttt ttttgtttgc 1200
aagcagcaga ttacgcgcag aaaaaaagga tctcaagaag atcctttgat cttttctacg 1260
gggtctgacg ctcagtgga cgaaaactca cgtaaggga ttttgggtcat gagattatca 1320
aaaaggatct tcacctagat ctttttaaat taaaaatgaa gtttttaaat aatctaaagt 1380
atatatgagt aaacttggtc tgacagttac caatgcttaa tcagtgggc acctatctca 1440
gcgatctgtc tatttcgctt atccatagtt gcctgactcc ccgtcgtgta gataactacg 1500

```

atacgggagg	gcttaccatc	tggccccagt	gctgcaatga	taccgcgaga	cccacgctca	1560
ccgggtccag	atztatcagc	aataaaccag	ccagccggaa	gggcccagcg	cagaagtggg	1620
cctgcaactt	tatccgcctc	catccagttc	attaattggt	gccgggaagc	tagagtaagt	1680
agttcgcgag	ttaatatgtt	gcgcaacggt	gttggcattg	ctacaggcat	cgtgggtgtca	1740
cgctcgtcgt	ttggtatggc	ttcattcagc	tccggttccc	aacgatcaag	gcgagttaca	1800
tgatccccc	tggtgtgcaa	aaaagcgggt	agctccttcg	gtcctccgat	cggtgtcaga	1860
agtaagtgg	ccgcagtggt	atcactcatg	gttatggcag	cactgcataa	ttctcttact	1920
gtcatgccat	ccgtaagatg	cttttctgtg	actggtgagt	actcaaccaa	gtcattctga	1980
gaataccgcg	cccggcgacc	gagttgctct	tgccccggcg	caatacggga	taatagtgt	2040
tgacatagca	gaacttttaa	agtgtctatc	attggaaaac	gttcttcggg	gcgaaaactc	2100
tcaaggatct	taccgctggt	gagatccagt	tcgatgtaac	ccactcgtgc	acccaactga	2160
tcttcagcat	cttttacttt	caccagcggt	tctgggtgag	caaaaacagg	aaggcaaaat	2220
gccgcaaaaa	agggataaag	ggcgacacgg	aaatgttgaa	tactcatact	cttctttttt	2280
caatattatt	gaagcattta	tcaggggtat	tgtctcatga	gcggatacat	atttgaatgt	2340
atttagaaaa	ataaacaat	aggggttccg	cgcacatttc	cccgaagaat	gccacctgac	2400
gtctaagaaa	ccattattat	catgacatta	acctataaaa	ataggcggtat	cacgaggccc	2460
ttctgctcgc	cgtgtttcgg	tgatgacggg	gaaaacctct	gacacatgca	gctcccgag	2520
acggtcacag	cttggtctgta	agcggatgcc	gggagcagac	aagcccgctca	gggcgctgca	2580
gcgggtgttg	gcgggtgtcg	gggtggtctt	aactatgcgg	catcagagca	gattgtactg	2640
agagtgcacc	atatgcggtg	tgaaataccg	cacagatgcg	taaggagaaa	ataccgcctc	2700
aggcgaaatt	gtaaacgtta	atattttgtt	aaaattcgcg	ttaaatattt	gttaaatcag	2760
ctcatttttt	aaccaatagg	ccgaaatcgg	caaaatccct	tataaatcaa	aagaatagac	2820
cgagataggg	ttgagtgttg	ttccagtttg	gaacaagagt	ccactattaa	agaacgtgga	2880
ctccaacgtc	aaagggcgaa	aaaccgtcta	tcagggcgat	ggcccactac	gtgaaccatc	2940
acccaaatca	agttttttgc	ggtcgaggtg	ccgtaaagct	ctaaatcgga	accctaaagg	3000
gagcccccca	tttagagctt	gacggggaaa	gccggcgaa	gtggcgagaa	aggaagggaa	3060
gaaagcgaaa	ggagcggggc	ctagggcgct	ggcaagtgt	gcggtcacgc	tgcgcgtaac	3120
caccacaccc	gccgcgctta	atgcgcgcgt	acagggcgcg	tccattcgcc	atcaggctg	3180
cgagataggt	gggaaggcg	atcgggtcgg	gcctcttcgc	tattacgcca	gctggcgaaa	3240
gggggatgtg	ctgcaaggcg	attaagttgg	gtaacgccag	ggttttccca	gtcacgacgt	3300
tgtaaaacga	cggccagtga	attgtaatac	gactcactat	agggcggaat	caaaaaaccc	3360
ctcaagaccc	gttttagagg	cccaaggggt	tatgctagt	aattctgcag	ggtacccggg	3420
gaccccttag	agatccctcg	acctcgagat	ccattgtgct	ggaaagcctt	tgcaaggctg	3480
gcaagccacg	tttggtggtg	gcgaccatcc	tccaaaatca	acaagtttgt	acaaaaaagc	3540
aggctatgcc	aagtacatgt	cgattgcgta	cgcggttcgta	atgttggctg	tgtagtgcgc	3600
taccagcagt	caaattgttc	tcgagagtgc	gtttttacat	tatcccttca	tcctgattac	3660
gacaattttc	agctgtttct	gtcctacat	ctctcttcat	tgtcacaatg	gtcggaaatct	3720
tcttctttgc	tgcatgtctt	catccaaaag	aattcacgaa	tattatccat	ggtgtcgtat	3780
tcttctctcat	gattccatct	acatatgtgt	tcctcacttt	atattcgctc	atcaatctca	3840
acgttatcac	gtggggaaact	cgtgaagctg	tcgctaaggc	aacgggacaa	aagacgaaaa	3900
aagcgcctat	ggaacaattt	atagacagag	tgattgat	tgtagaaaag	ggattcagat	3960
taatcagttg	tcgggagaag	aaggacatg	aagagagacg	agagaaaatg	gaaaagaaaa	4020
tgagagaaat	ggagctagcc	ttgagaagta	ttgaggttat	ctttaacttt	agaaatgtga	4080
aattaataat	ttattttcag	agtgggtgcc	acgtgaagaa	aattctcgat	gcaacagagg	4140
agaaggagaa	acgtgaagaa	gaaactcaaa	ctgcagattt	tccgattgaa	gagaacgtag	4200
agaagactca	aaaagagatt	cagaaggcaa	accgttatgt	gtggatgaca	agtcatagct	4260
tgaaagtgtg	tgaacgagga	aaactgaaaa	gtgcggaaaa	ggttttctgg	aacgagctca	4320
tcaatgcata	tctgaaaccg	atcaagacga	cgccagctga	aatgaaagcc	gtcgccgaag	4380
gattggcttc	tctacgaaat	cagattgctt	tcactattct	tctcgtaaat	tctcttcttg	4440
ctcttgccat	ctttttgatt	cagaaacaca	aaaatgtgct	cagcatcaag	ttctcgccaa	4500
tcagtaagca	atattaccct	tatggtaaat	tcaaaaaatt	tggttttttt	ttctagaaaa	4560
cttccgatgg	acgaaaatga	atgagatgac	tggaacaatac	gaggaaaaccg	atgaaccatt	4620
aaaaatagat	ccacttgga	tggaattgt	tggttttctt	ctaattattc	tttttgttca	4680
aactctcgga	atgcttctcc	a				4701

&lt;210&gt; 7

&lt;211&gt; 25

&lt;212&gt; DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:  
Oligonucleotide primer C04H5.6F

<400> 7

tgctcagaga gtttctcaac gaacc

25

<210> 8

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide  
primer C04H5.6R

<400> 8

caatgttagt tgctaggacc acctg

25

<210> 9

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide  
primer K11D9.2bF

<400> 9

cagccgatct ccgtcttgtg

20

<210> 10

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide  
primer K11D9.2bR

<400> 10

ccgagggcaa gacaacgaag

20

<210> 11

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide  
primer Y57G11C.15F

<400> 11

accgtggtac tcttatggag ctcg

24

<210> 12

<211> 20  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide  
primer Y57G11C.15R

<400> 12  
tgcaagtggat tgggtcttcg 20

<210> 13  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide  
primer T25G3.2F

<400> 13  
ggggacaagt ttgtacaaaa aagcaggcta tgccaagtac atgtcgattg cg 52

<210> 14  
<211> 52  
<212> DNA  
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Oligonucleotide  
primer T25G3.2R

<400> 14  
ggggaccact ttgtacaaga aagctggggtt ggagaagcat tccgagagtt tg 52

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/10 C12N9/22 C07K14/435 C12N15/66 C12N15/70  
C12N1/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TIMMONS L ET AL: "Specific interference by ingested dsRNA" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 395, no. 6705, 29 October 1998 (1998-10-29), page 854 XP002103601 ISSN: 0028-0836 the whole document	1-4, 12-21, 23-25, 28-31, 34-39
A	FIRE A ET AL: "Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans" NATURE, GB, MACMILLAN JOURNALS LTD. LONDON, vol. 391, 19 February 1998 (1998-02-19), pages 806-811, XP002095876 ISSN: 0028-0836 cited in the application the whole document	1-4

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

5 July 2001

Date of mailing of the international search report

20/07/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Mateo Rosell, A.M.

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SHARP PHILLIP A: "RNAi and double-strand RNA." GENES & DEVELOPMENT, vol. 13, no. 2, 15 January 1999 (1999-01-15), pages 139-141, XP002171268 ISSN: 0890-9369 the whole document ---	1-4
A	RAY C ET AL: "GUT-SPECIFIC AND DEVELOPMENTAL EXPRESSION OF A CAENORHABDITIS ELEGANS CYSTEINE PROTEASE GENE" MOLECULAR AND BIOCHEMICAL PARASITOLOGY,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 51, 1992, pages 239-249, XP000572340 ISSN: 0166-6851 abstract ---	2-4,8
A	RAND J B ET AL: "GENETIC PHARMACOLOGY: INTERACTIONS BETWEEN DRUGS AND GENE PRODUCTS IN CAENORHABDITIS ELEGANS" METHODS IN CELL BIOLOGY,LONDON,GB, vol. 84, 1995, pages 187-204, XP000956211 page 190, paragraph 1 -page 194, paragraph 4 ---	1-4,8
A	AVERY LEON ET AL: "The Caenorhabditis elegans unc-31 gene affects multiple nervous system-controlled functions." GENETICS, vol. 134, no. 2, 1993, pages 455-464, XP001011453 ISSN: 0016-6731 the whole document ---	2-4,8
A	TAGESSON C ET AL: "INFLUENCE OF SURFACE-ACTIVE FOOD ADDITIVES ON THE INTEGRITY AND PERMEABILITY OF RAT INTESTINAL MUCOSA" FOOD AND CHEMICAL TOXICOLOGY, vol. 22, no. 11, 1984, pages 861-864, XP001009621 ISSN: 0278-6915 the whole document --- -/--	8

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	<p>LYON CHRISTOPHER J ET AL: "The C. elegans apoptotic nuclease NUC-1 is related in sequence and activity to mammalian DNase II."</p> <p>GENE (AMSTERDAM), vol. 252, no. 1-2, 11 July 2000 (2000-07-11), pages 147-154, XP001009494 ISSN: 0378-1119 abstract; figure 3 page 151, right-hand column, paragraph 2 -page 153, right-hand column, paragraph 2</p> <p>---</p>	6,7
P,X	<p>WO 00 01846 A (MORTIER KATHERINE ;DEVGEN NV (BE); BOGAERT THIERRY (BE); PLAETINCK) 13 January 2000 (2000-01-13) cited in the application</p> <p>page 8, line 9 -page 10, line 22 page 12, line 14 -page 23, line 2 figures 5,9; examples 1-4</p> <p>---</p>	1-4, 12-21, 23-25, 28-31, 34-39
P,X	<p>WO 00 63425 A (FEICHTINGER RICHARD ;BEGHYN MYRIAM (BE); DEVGEN NV (BE); BOGAERT T) 26 October 2000 (2000-10-26) abstract page 2, line 14-30 page 6, line 18-33 page 7, line 12 -page 9, line 28 page 12, line 20 -page 13, line 25; example 3</p> <p>---</p>	2-5,8,9, 29-33
T	<p>TIMMONS LISA ET AL: "Ingestion of bacterially expressed dsRNAs can produce specific and potent genetic interference in Caenorhabditis elegans."</p> <p>GENE (AMSTERDAM), vol. 263, no. 1-2, 2001, pages 103-112, XP001009512 ISSN: 0378-1119 the whole document</p> <p>-----</p>	1-4, 12-21, 23-26, 28-31, 34-39

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0001846 A	13-01-2000	AU 4907999 A	24-01-2000
		EP 1093526 A	25-04-2001
		GB 2349885 A	15-11-2000
		NO 20010019 A	05-03-2001
<hr/>			
WO 0063425 A	26-10-2000	AU 3984600 A	02-11-2000
		GB 2351152 A	20-12-2000
<hr/>			



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**